THE PRINCIPLES AND PRACTICE OF HAEMODIALYSIS

THE EXPERIENCE AT THE KENYATTA NATIONAL HOSPITAL

BY

DR. SETH OMAH MC'LIGEYO, M.B., CH.B. (NAIROBI), 1981

A THESIS SUBMITTED IN PART FULFILMENT FOR THE DEGREE OF MASTER OF MEDICINE (MEDICINE) IN THE UNIVERSITY OF NAIROBI
DECLARATION

This thesis is my original work and has not been presented for a degree in any other University.

Signed

DR. S. O. MC'CLIGEYO, M.B., Ch.B., (NAIROBI)

This thesis has been submitted for the degree of Master of Medicine with my approval as a University supervisor.

Signed

DR. L. S. OTIENO, M.B., Ch.B. (EA), M.R.C.P. (UK) F.I.C.A., (USA)
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>TITLE</td>
<td>i</td>
</tr>
<tr>
<td>DECLARATION</td>
<td>ii</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>iv</td>
</tr>
<tr>
<td>LIST OF PHOTOGRAPHS</td>
<td>v</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>vi</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>viii</td>
</tr>
<tr>
<td>DIALYSIS - A POEM</td>
<td>ix</td>
</tr>
<tr>
<td>SUMMARY</td>
<td>x</td>
</tr>
<tr>
<td>1. INTRODUCTION</td>
<td></td>
</tr>
<tr>
<td>1 (i) Historical Background</td>
<td>1</td>
</tr>
<tr>
<td>1 (ii) Haemodialysis equipment</td>
<td>4</td>
</tr>
<tr>
<td>1 (iii) Vascular access for Haemodialysis</td>
<td>16</td>
</tr>
<tr>
<td>1 (iv) Principles of Haemodialysis</td>
<td>18</td>
</tr>
<tr>
<td>1 (v) Indications for Haemodialysis</td>
<td>22</td>
</tr>
<tr>
<td>1 (vi) Complications in Haemodialysis</td>
<td>23</td>
</tr>
<tr>
<td>1 (vii) Mortality in Patients on Haemodialysis</td>
<td>31</td>
</tr>
<tr>
<td>1 (viii) Haemodialysis - The African Situation</td>
<td>31</td>
</tr>
<tr>
<td>11. MATERIALS AND METHODS</td>
<td></td>
</tr>
<tr>
<td>11 (i) Retrospective study</td>
<td>32</td>
</tr>
<tr>
<td>11 (ii) Prospective study</td>
<td>36</td>
</tr>
<tr>
<td>111. RESULTS</td>
<td></td>
</tr>
<tr>
<td>111 (i)</td>
<td>43</td>
</tr>
<tr>
<td>111 (ii)</td>
<td>79</td>
</tr>
<tr>
<td>111 (iii)</td>
<td></td>
</tr>
<tr>
<td>V. DISCUSSION</td>
<td>92</td>
</tr>
<tr>
<td>V. REFERENCES</td>
<td></td>
</tr>
<tr>
<td>V1. APPENDIX</td>
<td>117</td>
</tr>
<tr>
<td>FIGURES</td>
<td>Page</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>1. Figure 1: Schematic view of Haemodialysis system</td>
<td>13</td>
</tr>
<tr>
<td>2. Figure 2: Diagrammatic representation of the natural and artificial kidney.</td>
<td>20</td>
</tr>
<tr>
<td>3. Figure 3: Age and sex distribution of the patients who underwent haemodialysis between July 1973 and June 1982.</td>
<td>44</td>
</tr>
<tr>
<td>4. Figure 4: The Distribution of patients who have undergone haemodialysis by syndromes.</td>
<td>45</td>
</tr>
<tr>
<td>5. Figure 5: Number of patients dialysed during each year beginning July 1973.</td>
<td>46</td>
</tr>
<tr>
<td>6. Figure 6: Age and sex distribution of the patients who underwent haemodialysis between August 1984 and August 1985.</td>
<td>55</td>
</tr>
<tr>
<td>7. Figure 7: Representation of cannulations related to individual dialysis programmes.</td>
<td>69</td>
</tr>
<tr>
<td>8. Figure 8: The duration of haemodialysis and Ascites and the temporal relation of each.</td>
<td>76</td>
</tr>
</tbody>
</table>
PHOTOGRAPHS

1. Photograph 1: A Gambro Lundia Plate (standard), a parallel flow dialyser.

2. Photograph 2: Two different types of coil dialysers.

3. Photograph 3: Two different types of hollow fibre dialysers.

4. Photograph 4: Haemodialysis equipment at Kenyatta National Hospital (July 1973 to June 1982).

5. Photograph 5: Arteriovenous shunt in place in one of the patients dialysed between August 1984 and August 1985.

6. Photograph 6: A patient on haemodialysis using the Gambro type machine.

7. Photograph 7: Part of the reverse osmosis equipment at Kenyatta National Hospital.

8. Photograph 8: An infected cannula site.

9. Photograph 9: Gross oedema of the hand following the fashioning of an arteriovenous shunt.

10. Photograph 10: A patient considered to have Idiopathic ascites of haemodialysis.
<table>
<thead>
<tr>
<th>TABLES</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Table 1:</td>
<td>Causes of acute renal failure in patients dialysed between July 1973 and June 1982.</td>
<td>43</td>
</tr>
<tr>
<td>2. Table 2:</td>
<td>Presumed causes of chronic renal failure in patients dialysed between July 1973 and June 1982.</td>
<td>47</td>
</tr>
<tr>
<td>3. Table 3:</td>
<td>The frequency of some symptoms in renal failure patients at the onset of haemodialysis (July 1973 - June 1982).</td>
<td>48</td>
</tr>
<tr>
<td>4. Table 4:</td>
<td>The frequency of some clinical features in renal failure patients at the onset of haemodialysis (July 1973 to June 1982).</td>
<td>49</td>
</tr>
<tr>
<td>5. Table 5:</td>
<td>Pre-dialysis biochemical parameters in acute renal failure patients (July 1973 to June 1982).</td>
<td>51</td>
</tr>
<tr>
<td>6. Table 6:</td>
<td>Pre-dialysis biochemical parameters in chronic renal failure patients (July 1973 to June 1982).</td>
<td>52</td>
</tr>
<tr>
<td>7. Table 7:</td>
<td>The frequency of some symptoms in renal failure patients at the onset of haemodialysis (August 1984 - August 1985).</td>
<td>56</td>
</tr>
<tr>
<td>8. Table 8:</td>
<td>The frequency of some clinical features in renal failure patients at the onset of haemodialysis (August 1984 - August 1985).</td>
<td>57</td>
</tr>
<tr>
<td>9. Table 9:</td>
<td>Summary of experience - Acute Renal Failure on haemodialysis.</td>
<td>58</td>
</tr>
<tr>
<td>10. Table 10:</td>
<td>Causes of Death-Acute Renal Failure on haemodialysis.</td>
<td>59</td>
</tr>
<tr>
<td>Table</td>
<td>Title</td>
<td>Page</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>11.</td>
<td>Table II: Summary of experience-Chronic Renal Failure patients on haemodialysis.</td>
<td>62</td>
</tr>
<tr>
<td>12.</td>
<td>Table 12: Causes of Death-Chronic Renal Failure patients on haemodialysis.</td>
<td>65</td>
</tr>
<tr>
<td>13.</td>
<td>Table 13: Pre-programme and the latest predialysis blood pressures.</td>
<td>70</td>
</tr>
<tr>
<td>14.</td>
<td>Table 14: Clinical features of eight patients with ascites during haemodialysis.</td>
<td>73</td>
</tr>
<tr>
<td>15.</td>
<td>Table 15: Pertinent laboratory data on patients with ascites during haemodialysis.</td>
<td>74</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENTS

1. To Dr. Otieno, L. S. of the Department of Medicine for his guidance ever since I made up my mind to write a dissertation on something relevant to the practice of Nephrology at Kenyatta National Hospital.

2. To Kamau, Bonnie, Purity, Fundi, Karanja and Gladys for their secretarial assistance during the preliminary write ups of the dissertation.

3. To Gladys, without whose excellent secretarial help, the final write up would not look like what it is today.

4. To my wife Susan, who bore with me during these long and trying periods.
I

The Travenol salesman wears glasses and a dark suit:

"Do you
Take this machine
In sickness and in health
Till death do you part?"
I do.

II

Reclining
On the nausea-green hospital chair:
Below me children, playing in the street;
Above me old men, dying of coronaries
I am
The final essence of the technological age,
Flesh conjoined with plastic, vessels with
steel, coils, alarms, twisted tubing
turning scarlet
Deep within the machine dark blood
Mixing with fluid, cellophane separated,
Plugged in and turned on.
Dear God
Purify me.

By

MICHAEL SAPPERSTEIN (a patient on a programme of maintenance haemodialysis)
Haemodialysis as a form of renal failure treatment was started at Kenyatta National Hospital in December 1972 with the opening of the Intensive Care Unit. Between that time and June 1982, the machines used were part of a commodity aid from Japan given to the Kenya Government. In that period haemodialysis was carried out irregularly, a total of 57 patients were dialysed. Of these 25 were females and 32 were males, 31 had acute renal failure, 18 had chronic renal failure and 8 had acute on chronic renal failure. The age range was 9 years to 50 years, with a mean age of 29.6 ± 3.6 (± 2SD), the commonest cause of acute renal failure was sepsis with disseminated intravascular coagulation and haemorrhage (32.3%) in various clinical settings. Chronic glomerulonephritis was the commonest cause of chronic renal failure (46.2%). At this time haemodialysis was geared mainly towards patients with acute renal failure who were expected to regain their renal function. 61.3% of the patients with acute renal failure started on haemodialysis died. The commonest cause of death was continuing uraemia (31.6%) due to irregular and inadequate dialysis.

The patients started on dialysis in this period were severely ill and had adverse biochemical parameters.

In the one year period, beginning August 1984 in the renal Unit at Kenyatta National Hospital, intermittent haemodialysis has been carried out regularly. This followed the installation of Gambro type haemodialysis machines in the Unit early in 1984. The machines were part of a commodity aid from West Germany given to the Kenya Government and the renal Unit where haemodialysis is being carried out was built by the Kenya Government. In the one year period, 42 patients have been haemodialysed. These include 20 with acute renal failure and 22 with chronic renal failure, deliberately started on maintenance haemodialysis. Haemorrhage in various clinical settings was the commonest cause of acute renal failure (50%). The commonest cause of chronic renal failure was chronic glomerulonephritis (59.1%). 30% of the patients with acute renal failure started on haemodialysis died. None of the deaths was related to the dialysis procedure. In the patients with chronic renal failure started on haemodialysis, 72.7% died. The commonest cause of death was interdialytic pulmonary oedema (31.3%). The concept of "prophylactic" dialysis was used in the patients with acute renal failure in the prospective period. Thus they were in a better clinical state and had less adverse biochemical parameters than the patients dialysed between December 1972 and June 1982. The outcome of the dialytic treatment was favourable.
The management of 22 patients with chronic renal failure on maintenance haemodialysis for periods of upto 36 weeks (170 patient-weeks) is described.

The clinical and biochemical states of the patients at the start of treatment were poor. The initial control of blood pressure and biochemical response to dialytic treatment were encouraging. The commonest recurring problem in the short term has been related to vascular access.
INTRODUCTION

I. (1) HISTORICAL BACKGROUND

Although modern active haemodialysis is almost 30 years old, dialysis was known to the Roman civilisation 18 centuries ago (1). At the time hot water bath was used to produce profuse sweating through the skin (semi-permeable membrane) making the patients lose their toxins into the water. This method apparently existed into the 1850s. Thomas Graham, a chemist, however, in 1854 defined dialysis as we know it today. He caused movements of solutes through semi-permeable membranes made from ox bladders (2).

The possibility of long-term haemodialysis may have been envisioned by Abel (3) in 1913 when he first described in vivo dialysis and speculated on its eventual use in the treatment of "numerous toxic states in which the eliminating organs of the body, more especially the kidneys, are incapable of removing at an adequate rate the natural or unnatural substances whose accumulation is detrimental to life" (4). The artificial kidney he used was composed of numerous parallel flow cellulose tubes. Hirudin obtained from the heads of leeches was used as an anti-coagulant. Thirty odd years of sporadic experimentation and limited technical advance passed before Abel's Prophecy was fulfilled in the primary sense of "tiding over a crisis" of acute renal failure. By successfully treating a number of temporarily oliguric patients with a rotating drum of his own design, Kolff (5-7) laid the foundation for the use of the artificial kidney in clinical medicine. In the middle 1940s Alwall (8) had developed the vertical drum kidneys, however Kolff's invention remained the most widely used and most effective of all artificial kidneys until 1960 when Kiil of Norway developed the flat plate parallel
flow artificial kidney.

General acceptance of the use of artificial kidney in the management of acute renal failure was slow. Dialytic procedures in their early days were inordinately complex (9-11). Results were variable, and convincing evidence that dialysis could reduce mortality rates was difficult to gather (12). For these reasons, together with an unfortunate polarisation of attitudes among nephrologists, more technical refinement and vastly expanded clinical experience was required to establish this procedures as an essential component of modern treatment for acute renal failure.

A realisation of the full potential of haemodialysis in the management of permanent irreversible renal failure was similarly slow to develop and for somewhat similar reasons. Early attempts to prolong life in chronic renal failure through repeated dialysis were uniformly disappointing. Alwall et al (13) succeeded in keeping several irreversibly oliguric patients for as long as 116 days. The intervals between dialytic treatment in these instances, however, were relatively long. In each case uraemia followed a sawtooth pattern of sweeping amplitude, and the patient's condition deteriorated with malnutrition and other complications, particularly infection, occurring. Although the therapeutic investment in these cases was truly heroic, motivation derived more from a hope, albeit dwindling with time, that adequate renal function would eventually return, than from a conviction that rehabilitation could be achieved through indefinite continuation of treatment.
A significant step towards more effective use of the artificial kidney in severe, prolonged renal failure was made by Teschan and associates (14). They espoused the concept of "Prophylactic" daily dialysis to prevent, rather than correct the symptoms of profound uremia. They also devised a technique for avoiding frequent cutdowns through the use of indwelling arterial and venous catheters flushed hourly with heparin. No deliberate attempt was made, however, to exploit this approach as indefinite substitution therapy for recognised, irreversible chronic renal failure. Accordingly, during the 1950s, haemodialysis was deemed of limited value in the treatment of chronic renal failure (15, 16). It was conceded to be helpful in treating the exacerbations of chronic mild uraemia and in preparing uraemic patients for surgery.

Despite the development of the hardware for effective dialysis, a major stumbling block to the long term application of dialysis remained. Each time a patient had to be dialysed a surgical cutdown was necessary and glass tubing had to be fired, shaped and inserted into the vessel. Attached rubber tubing completed the means for keeping circulatory access open between dialysis. It was not until 1960 that Scribner and his associates (17, 31) reported the first deliberate attempt to restore useful life through repeated dialysis of a patient with obviously terminal, irreversible renal disease. One critical factor which facilitated success in this pioneering effort was the development of an ingeniously simple method for gaining access to the patient's circulation repeatedly and conveniently without repeated cutdowns (18). The permanently indwelling Teflon-Silastic cannulas, con-
nected together when not in use to form an arterio-venous shunt, ushered in a new era for the artificial kidney.

As a further development in vascular access Cimino and associates (19, 37) developed an internal fistula - the artificial arteriovenous fistula as we know it today (20) by operative manoeuvre whereby a suitable artery and vein in the limbs were connected together in order to make the vessels appear prominent and hence easily accessible for frequent punctures for haemodialysis.

The development and improvement of haemodialysis also provoked thoughts on how helpful a patient could be to herself or himself. A London group in 1961 successfully trained a patient to look after himself at his home by knowing how to set up his machine and look after it during dialysis (21). This was followed by overnight dialysis at home by the same group in 1964 (22). In America home dialysis scheme had been proposed but was successfully put into operation also in 1964.

As a continuation in the development of artificial kidneys, Stewart, a chemist from Michigan, introduced the Hollow fibre for capillary flow dialysis in 1960 (23).

From the foregoing modern day dialysis is a challenge to today's nephrologist who may be amazed by the advance in haemodialysis which has accrued over the years.

(ii) HAEMODIALYSIS EQUIPMENT

Extracorporeal haemodialysis requires a satisfactory membrane package for solute and water transport and fluid cycling equipment (24). As haemodialysis therapy has become more common-
place, a large variety of dialysers and associated equipment has become available.

DIALYSERS

A dialyser is a device which separates two fluid media of differing composition and allows a partial exchange of their constituents from one to the other. The term haemodialyser is used to refer to a device which contains part of the circulating blood outside the body and which is so constructed as to allow the exchange of blood chemicals to take place across a membrane into another fluid commonly called dialysate, without the two mixing.

There are three designs of dialysers in clinical use today (24, 25):

1. The parallel flow dialyser (photograph 1)
2. The coil dialyser (photograph 2)
3. The hollow fibre dialyser (photograph 3)

Dialysers are basically membrane support systems. They must hold the membrane in such a fashion that blood and dialysate flow in an optimum manner on each of their respective membrane sides. Dialyser design and membrane properties maintain a degree of independence for a variety of membranes can be used in most available dialyser designs; and the various designs can use different membranes, with the possible exception of the hollow fibre, a limitation is imposed on the configuration of the dialyser, since the capillary fibre is its own support.

Cellulose base membranes of one sort or another constitute over 95 per cent of the membranes in current clinical use (24).
Photograph 1: A Gambro Lundia Plate (standard), a parallel flow dialyser.
Photograph 2: Two different types of coil dialysers.
Photograph 3: Two different types of hollow fibre dialysers.

A coil dialyser extreme left.
Cuprophan has been the standard against which other membranes are compared. Alternative membranes that are available include Polycarbonate, Polyacrylonitrile and Polysulfone membranes (26).

In considering a membrane for haemodialysis, the following properties are important (27):

1. Permeability properties: diffusive permeability of solutes and hydraulic permeability of the solvent.

2. Mechanical properties: tear strength, dimensional changes on wetting, resistance to elongation with time, and stress-strain resistance.

3. Toxic properties: release of toxic components from the membrane causing tissue damage.

4. Thrombogenic and haemolytic properties: alteration in blood clotting, platelet function and red blood cells damage by the membrane.

Aside from safety and nontoxicity of the materials used in the construction of the dialyser, other properties of major concern include:

1. The priming volume;

2. The ability to recover the blood after completion of dialysis;

3. The resistance of blood flow; and

4. The ability to clear waste products from the blood and to remove water.
DIALYSATE FLUID

Dialysate fluid is an aqueous mixture of the principal electrolytes in extracellular fluid. Dialysate is made by either mixing a premeasured quantity of salts in a reservoir of warm water, or proportionally mixing a concentrated salt solution with an appropriate amount of warm water continuously. The former method has been called the batch system, the latter the proportional delivery system.

One of the first considerations in preparing a dialysate solution is the quality of water used. When haemodialysis was in its infancy, untreated water from the city water was frequently employed. As chronic haemodialysis expanded, it became evident that careful attention to the quality of water could prevent certain serious medical problems (28, 29). Basically, a water treatment system consists of a combination of filters, ion exchangers, or reverse osmosis devices. Sediment filters are routinely used to remove particulate matter above five microns in diameter. Absorptive carbon filters are advocated if free chlorine, chloramines or pyrogens are present in the water. Absorptive iron filters may be required if there is any iron present.

Ion exchangers are of two types: a water softener and a deioniser. A water softener is frequently used ahead of a reverse osmosis system because excessive hardness in the water feeding the reverse osmosis system may damage its membranes. Deionisers remove both cations and anions, exchanging them for hydrogen and hydroxyl groups in the water. They work most
efficiently to polish water after it is passed through the reverse osmosis process.

Reverse osmosis is a filtration process by which water is forced under high pressure against a membrane, allowing nearly pure water to pass. The process removes about 90 per cent of dissolved solids (28), and its effectiveness in delivering pure water is greatest when the feed water has been pretreated by filtration and softening.

The selection of a concentrate to mix with water to make the final dialysate has usually centred on its potassium, calcium and sodium content. The approximate concentration of ions in millimoles per liter in the final dialysate is most often 1.75 for calcium, 1.0 for magnesium, 2.0 for potassium, 33 for acetate, 132 for sodium, 105 for chloride, 200 mg/dl for dextrose. These figures are chosen to correct the electrolyte changes in various renal failure syndromes.

DIALYSATE SUPPLY SYSTEMS

The purpose of a dialysate supply system is to mix dialysis concentrate with water in an appropriate composition and to transport the final dialysate fluid along the membrane surface opposite the surface of the circulating blood.

There are individual batch and proportioning system, as well as central supply systems capable of supplying dialysate for as many as twenty patients simultaneously. The decision to use an individual supply system versus a central system is dependent mostly on economics. However, the flexibility of being able to vary the dialysate composition according to the patient needs is
retained only through the individual supply systems. One of the most widely used systems is the so-called recirculating single-pass dialysate delivery system used almost exclusively with the coil-type haemodialysers. This system consists of a cannister which holds the coil dialyser in place while dialysis fluid bathes the coil. The dialysis fluid is drained away from the cannister at a rate of 300 - 400 mls/mm and discarded as fresh dialysate is replenished in the cannister at the same rate. This type of system is adaptable to either a proportioning mixture or a batch mixer.

In parallel-flow dialysers and in hollow fibre dialysers, a system better suited to their use is the so-called single-pass dialysate delivery system. In principle, a fresh dialysate solution is passed countercurrent to the flow of blood and then discarded.

MONITORS

It is important that the haemodialysis procedures be monitored by various devices to ensure maximum safety. The parameters commonly monitored are:

1. The conductivity and temperature of dialysate
2. Blood leaks
3. Arterial and venous pressures
4. Tubing collapse
5. Air bubbles
Figure 1: Schematic view of haemodialysis system.
KEY TO FIGURE 1

\( C_{Bi} \) - Concentration, whole blood, at inlet of dialyser, variable units.

\( C_{Bo} \) - Concentration, whole blood, at outlet of dialyser, variable units.

\( C_D \) - Concentration at dialysate inlet, variable mass units/ml unless specified differently.

\( C_{Do} \) - Concentration at dialysate outlet, variable mass units/ml unless specified differently.

\( P_{AF} \) - Pressure arterial fistula needle, mm Hg.

\( P_{Bi} \) - Pressure blood inlet, mm Hg.

\( P_{Do} \) - Pressure dialysate outlet, mm Hg.

\( P_{Di} \) - Pressure dialysate inlet, mm Hg.

\( P_{Bo} \) - Pressure blood outlet, mm Hg.
BLOOD LINE TUBING

Connection of the dialyser to the patient requires additional equipment and supplies. Polyvinylchloride tubing is commonly used for blood tubing connections between the patient's vascular bed and the dialyser. These are fabricated with segments for blood sampling, heparin administration, bubble traps, segments which fit into blood pumps, and an arm of tubing for the administration of fluids during dialysis.

A filter in the venous bubble trap is necessary to minimise the risk of pulmonary embolization.

Blood pumps are almost always used to maintain flow through the dialyser. Blood pumping is performed with a roller pump. An inbuilt heparin pump is present in most dialysis machines.

SINGLE NEEDLE DIALYSIS

The invention of an oscillating system which allows blood to flow out of the body and back to the body through a single needle inserted into a peripheral vein has created a great deal of interest as a means of achieving extracorporeal circulation through a haemodialyser (30). The system consists of a cannula and a short Y connector. Fresh blood is drawn into the inflow line by a blood pump while the venous return is blocked. Alternatively, the inflow line is occluded by a clamp, while the outflow line is opened, allowing the return of blood from the dialyser to the patient. This is in contrast to the double needle depicted in figure 1.
(iii) VASCULAR ACCESS FOR HAEMODIALYSIS

The historical landmark of successful semipermanent cannulation of blood vessels was described by Quinton et al in 1960 (31). Since that time several modes of access to the patients' vasculature have been described.

EXTERNAL SHUNTS

The Quinton-Scribner shunts provided the initial feasibility for chronic haemodialysis (17, 31). These shunts provide flow rates of approximately 150 to 350 ml/min and have generally failed to produce cardiac strain or complications. Because of the high incidence of attendant cannula complications, external shunt systems have largely been supplanted by internal A-V fistula procedures in most dialysis centres. External shunts are often preferrable in specific clinical settings, e.g. short-term dialysis in patients awaiting renal transplantation; treatment of acute, reversible renal failures and whenever immediate haemodialysis is required (32). Arm locations permit technically easier operations but should be avoided in patients needing chronic dialysis. Placing an ankle shunt preserves arm blood vessels for future surgical construction of arteriovenous fistula.

Implantation of a teflon-silastic external shunt into the upper thigh (Groin shunt) is occasionally used (33). These are normally considered when confronting a patient who has no remaining access sites available in either arm or leg and who is in need of immediate dialysis.

Placing of teflon-silastic cannulas in the upper arm is
(iv) PRINCIPLES OF HAEMODIALYSIS

Currently, all extracorporeal haemodialysers that are practical for widespread clinical use employ a cellulose based membrane to separate blood from dialysis fluid. Mass transfer of solute and water across the membrane is dependent upon two fundamental processes, diffusion and ultrafiltration.

SOLUTE TRANSPORT BY DIFFUSION

Diffusion is the random thermal movement of molecules which, under the proper condition, can result in the transfer of mass from one position to another. When a solute such as urea is added to a fixed volume of water, the urea molecules when dissolved are in constant random motion and become distributed uniformly throughout the volume of water. The rate of this random movement of solute in water relates to molecular size, molecular shape, and ionic charge and is described by the diffusion coefficient of the species in water. The water molecules, too, are in constant random motion at a rate described by the diffusion coefficient for water in water. If the solution of urea is connected by aqueous channels that permit diffusion of the solute to another solution of different urea concentration, then the process of diffusion will result in a net transfer of urea (mass transfer) from the compartment of higher concentration to the compartment of lower concentration.

DIALYSANCE BY THE ARTIFICIAL KIDNEY

The function of haemodialysers may be described in the same way as the function of the kidney with respect to the removal of
substances from blood. In Fig. 2 the schematic representation of the kidney emphasizes the roles of hydraulically determined filtration by glomeruli and a variety of tubular processes that finally determined the output or clearance. In contrast, in the absence of ultrafiltration the haemodialyser operates as a simple diffusion device but nevertheless produces a calculable output or clearance (43).

For the kidney,

\[
\text{Clearance} = \frac{UV}{P} = \frac{QuCu}{CBi} = \frac{\text{mass out}}{\text{Blood concentration}}
\]

and for the haemodialyser

\[
\text{Clearance} = \frac{QBi(CBi-CBo)}{CBi} = \frac{\text{mass out}}{\text{Blood concentration}}
\]

Dialysance \( (D_B) \) has been defined as "the minute rate of net exchange of a substance between blood and bath fluid per unit blood-bath concentration gradient" (43). From Fig. 2 this description may be expressed mathematically as

\[
D_B = \frac{QBiCBi - QBoCBo}{CBi - CDi}
\]

In the absence of ultrafiltration the flow rates for blood entering and leaving the system are equal \( (Q_{Bi} = Q_{Bo}) \), and if single-pass dialysis is employed the concentration of solute in the entering dialysis fluid \( (CDi) \) is always zero. Therefore the expression can be simplified and re-written in a form similar to the usual clearance equation.

\[
D_B = \frac{QB (CB_i - CB_o)}{CBi}
\]
Figure 2. Diagrammatic representations of the natural and artificial kidney. The natural kidney (A) moves solute across the glomerular basement membrane convectively in response to a hydraulic force generated by blood pressure and the afferent (a) and efferent (e) resistance on either side of the glomerular capillary. In contrast, the artificial kidney (B) operates by diffusion across a membrane.

KEY TO FIGURE 2

QB - Blood flow rate.
CB - Concentration of substance in blood.
Qu - Urine flow rate.
Cu - Concentration of substance in urine.
CD - Dialysate flow rate.
CD - Concentration of substance in dialysate.
i - In
o - Out
ULTRAFILTRATION

Ultrafiltration is a process whereby bulk solution (water and dissolved permeant solutes) is transferred across the membrane by a gradient of hydrostatic pressure. In addition to regulating the composition of body fluids, the kidney has the important role of maintaining the volume of body fluid compartments. The haemodialyser may be used to achieve a net removal of body fluid through the process of ultrafiltration. Volume flow across a semipermeable membrane may be expressed as,

$$Q_F = A \cdot \frac{dP}{d\pi}$$

where

- \(Q_F\) = the flux rate for water across the membrane \(\text{cm}^3/\text{min}\)
- \(dP\) = the hydraulic pressure gradient from blood path to dialysis fluid path (mmHg).
- \((d\pi)\) = the osmotic pressure gradient from blood path to dialysis fluid path (mmHg).
- \(L_p\) = the hydraulic permeability, i.e. the volumetric flow rate of water per unit area of membrane per unit pressure gradient \(\text{cm}^3/(\text{min} \cdot \text{cm}^2 \cdot \text{mmHg})\)
- \(A\) = the area of the membrane.

Ultrafiltration in most haemodialysers is determined for all practical purposes by the hydraulic permeability of the membrane and the hydrostatic pressure applied to the blood side of the dialyser.
SOLUTE TRANSPORT BY CONVECTION

Convective transfer of solute occurs when permeant solute moves as a solution with water in response to either a hydrostatic or an Osmotic gradient.

(v) INDICATIONS FOR HAEMODIALYSIS

The well established indications for haemodialysis include:

1. Acute renal failure
2. Chronic renal failure
3. Acute intoxications (inadvertent drug over dosage and poisonings, acute metabolic derangements resulting in a toxic level of metabolites - lactic acidosis, hyperuricaemia, hypercalcaemia).
4. Overhydration

Proposed indications for dialysis have ranged from schizophrenia and myasthenia gravis (44) to Psoriasis (45). Early in the development of haemodialysis methodology the preferred therapeutic approach was to withhold haemodialysis until pressed to carry forward by some dire clinical or laboratory event. With the high level of technical competence now widely available, early application of haemodialysis is the rule. "Prophylactic" haemodialysis as advocated by Teschan et al (44) in 1960 is now routinely practised in acute renal failure.

In chronic renal failure, at a minimum, the following factors must be weighed in each case when deciding the time to initiate maintenance dialysis:

1. Degree of incapacity from uraemic symptoms.
2. Long-term expectations for maintenance dialysis: Is transplantation planned? if so, when?
(3) Presence of uraemic signs or symptoms or both: Uremic neuropathy, Pleuritis, Pericarditis, recurring infection and so on.

(4) Change in life-style imposed by beginning maintenance haemodialysis.

(5) The wishes (informed consent) of the patient and supporting family members.

Selection criteria for admission into a maintenance dialysis programme differ from centre to centre depending on such variables as availability of manpower and facilities for dialytic therapy.

(vi) COMPLICATIONS IN HAEMODIALYSIS

The complications of haemodialysis can be divided into those that are:

(1) Consequences of the usual dialysis procedure;

(2) Mechanical, iatrogenic or both, and

(3) Manifestations of persistent or incompletely treated uraemia.

(4) Problems of undetermined causes.

CONSEQUENCES OF THE USUAL HAEMODIALYSIS PROCEDURES

Haemodialysis can be viewed as two distinct phenomena: Clearance and ultrafiltration. Conceptual separation of clearance or diffusion and ultrafiltration is necessary for understanding the dialysis procedure and developing the proper approach to individual patients. One can utilize a rapid blood flow rate and large surface area dialyser to increase or maintain clearance, yet minimise fluid removal either by using low hydro-
static pressure or replacing a quantity of fluid equal to that removed. On the other hand, one can minimise clearance utilising a small dialyser with a slow blood flow rate while using maximum hydrostatic ultrafiltration to achieve greater fluid removal.

Changes In Vascular Volume: The most critical change that occurs with haemodialysis is reduction of extracellular volume by ultrafiltration. Insidious visceral engorgement, third space collection, and pulmonary oedema result from fluid overload. Hypertension in dialysis patients is also usually volume dependent (46), and the high incidence of cardiovascular disease in uremic patients largely results from the persistent fluid overload and resulting hypertension (47).

Several factors influence the likelihood of complications during fluid removal by dialysis:

(1) Volume of the dialyser and blood lines;

(2) Compliance of dialyser, that is the degree of expansion of the blood compartment with an increase in resistance to flow, and

(3) Magnitude of ultrafiltration.

A large extracorporeal circulation, a highly compliant dialyser, and an increased ultrafiltration coefficient are more likely to lead to hypotension than is a small surface area dialyser with a low ultrafiltration coefficient. Newer dialysing membranes allow a degree of ultrafiltration such that fluid can be removed from the vascular compartment faster than it can be replenished from interstitial and intercellular spaces, other
factors such as uraemic autonomic neuropathy (48), hormonal changes, and myocardial disease complicate efforts at reducing vascular volume. The potential adverse effects of antihypertensive medications as well as changes in osmolality and blood acetate concentration also should be assessed when one attempts ultrafiltration.

Controlled sequential ultrafiltration and haemodialysis, in which diffusion and ultrafiltration are separated, might allow a more stable dialysis and facilitate the removal of larger quantities of fluid (49, 50).

Electrolyte and Osmolar shifts: Abrupt changes in the concentration of sodium, potassium, and calcium during haemodialysis can induce serious consequences. Diffusion or clearance of electrolytes and other substances can create changes in intracellular and extracellular concentrations and can alter osmolality.

Most dialysate solutions have sodium concentrations between 130 and 140 mmol/litre. The lower sodium concentrations are used to remove sodium and thereby reduce blood pressure. However, patients frequently develop mild hyponatraemia, a chemical disorder that might be related to the development of side effects such as muscle cramps and dialysis disequilibrium. Severe dialysis disequilibrium is manifested by marked mental and psychiatric changes and grand mal seizures; a mild disequilibrium occurring after dialysis produces headache, fatigue and lethargy (51, 52). Rapid changes in the concentration of urea or other unidentified osmotically active agents (idiogenic osmoles) and changes in the pH of the central nervous system contribute to
the pathogenesis of this syndrome (52, 53). The rate of change of serum sodium, urea or other substance is probably more important than is the quantity of any substance removed. The syndrome usually can be prevented by avoiding prolonged and efficient dialysis, particularly when the blood urea nitrogen is markedly elevated. Intravenous osmotic agents such as mannitol or dextrose reduce the intensity of osmolar change and are believed by some to be effective in preventing muscle cramps and disequilibrium (54).

The most critical electrolyte shift in patients undergoing haemodialysis involves potassium. Hyperkalaemia often occurs in patients with advanced renal failure. This can be lowered by utilising a dialysate potassium concentration between 1.5 and 3.0 mmol/litre. In the patient with cardiac failure who takes digitalis, the patient with coronary disease and an irritable conduction system, or the small, elderly patient whose dietary intake is inadequate, a low potassium concentration in the dialysate can lead to transient hypokalaemia and severe rhythm disturbances.

Acetate Accumulation: In the early 1960s, acetate was developed as a dialysate buffer to avoid the use of complicated systems containing bicarbonate and bubbled carbon dioxide. It has been demonstrated that patients treated for long periods with acetate-buffered dialysate become bicarbonate depleted (55). In addition, transient acetate accumulation occurs during and immediately after dialysis in a significant percentage of patients (56). The acetate ion has been cited as a cause of myocardial depression (57) and cardiovascular instability in seriously ill patients (58).
Anticoagulation: Abnormalities of platelet factor III activity and platelet adhesiveness due to uraemia can be reversed by haemodialysis (59). Bleeding remains a risk, however, because systemic administration of heparin is necessary in carrying out extracorporeal circulation. Also, many dialysis patients are treated with warfarin, aspirin, and antiplatelet drugs to help preserve the patency of arteriovenous shunts and fistulas. These agents can induce a variety of bleeding complications including gastrointestinal haemorrhage; bloody pericardial, pleural, and joint effusion; subdural haematoma; retroperitoneal haematoma; ocular and retinal haemorrhage; and increased menstrual flow (60).

Shunt and fistula problems: The reported problems include:

1. Repeated thromboses requiring multiple operations (61).
2. Vascular compromise and vascular "steal" (62).
3. Infections (61)
   a. Local
   b. Endarteritis with septicaemia and septic emboli.
   c. Aneurysm with rupture
4. Increased cardiac output
5. Carpal tunnel syndrome (63)
6. Recirculation yielding inadequate dialysis

MECHANICAL AND IATROGENIC COMPLICATIONS OF HAEMODIALYSIS

Air embolus and the consequences of improper composition of the dialysate were devastating complications in the past, but improved automated equipment and safety features largely eliminated these problems. Haemodilution can occur from inadequate water treatment or contamination of the dialysate (64).
Other clinical problems such as dementia (65) hypertension and sudden death can result from dialysate contamination with substances such as aluminium, calcium, and fluoride. Toxic chemicals such as diethylthalate and polyvinyl chloride can be leached from membranes, dialyser shells, or blood lines and have been suggested as causes of cardiotoxicity (66), necrotizing dermatitis (67) and hepatitis (68).

The precipitous drop in the leukocyte count during haemodialysis is thought to result from activation of the complement system during exposure of blood to dialysis membranes. Leukocyte accumulation in the pulmonary vasculature has been held responsible for the pulmonary hypertension and hypoxaemia that occur in some patients (69). A fall in $P_{a\text{O}_2}$ also might be related to hypoventilation induced by the hypocapnia that results from a loss of carbon dioxide during dialysis (70).

Some deficiency states may occur during haemodialysis. This may be related to loss of folate, soluble B vitamins and amino acids across the dialysing membrane.

**MANIFESTATION OF PERSISTENT OR INCOMPLETELY TREATED URAEMIA**

Variable degrees of anaemia persist in most patients undergoing maintenance dialysis (71). Although this normochromic, normocytic anaemia primarily results from decreased erythropoiesis, other factors including endogenous haemodilution, low-grade blood loss, iron deficiency, and folate deficiency also contribute. Uraemic patients have compromised immune systems, and increased frequency of infection has been reported (72). Although haemodialysis tends to correct this immune deficiency
dialysis patients still seem to have an increased incidence of infection.

Pericarditis occurs at two different periods in patients with kidney failure. First, it often occurs just prior to, or soon after the induction of dialysis. Second, pericarditis can occur in patients who are dialysed chronically. In this setting, it can result from viral infection, or an underlying systemic disease. Gelfand et al. (73) have reported an increased incidence of pericardial effusion in uraemic patients being treated with minoxidil.

Some researchers have reported an acceleration of atherosclerotic cardiovascular disease in uraemic patients on dialysis (74), but some studies argue that atherosclerosis is not accelerated in this population (75).

Hyperparathyroidism does not respond to haemodialysis alone. In the patient with far advanced hyperparathyroidism, subtotal parathyroidectomy is sometimes necessary. In patients not treated appropriately, the end results can include severe proximal myopathy; severe bone disease with pathologic fractures and pain; and subcutaneous, joint, visceral, and vascular calcification (76).

Several types of encephalopathy can occur in patients undergoing chronic dialysis (77). Uraemic encephalopathy is common in patients with advanced renal insufficiency, and mild forms can appear in inadequately dialysed patients. A severe encephalopathy consisting of myoclonic jerking, speech impairment, dementia, and status epilepticus leading to death has
been recognised in long-term dialysis patients (78). Some researchers have suggested that orally administered Aluminium gels cause this syndrome of "Dialysis Dementia" (79). Others have indicated that the syndrome is related to aluminium in water used for dialysis (65, 80). Atherosclerotic cerebrovascular disease and subdural haematomas (81) must be distinguished from this syndrome.

Many chemical abnormalities can persist in patients on chronic dialysis, including hyperlipidaemia, mild acidosis, hyperuricaemia, hypermagnesaemia, hyperamylasaemia and elevated blood urea nitrogen and serum creatinine levels. Hypertriglyceridaemia and decreased high-density lipoprotein levels might contribute to premature atherosclerotic disease; hyperuricaemia might provoke gouty arthritis; and chronic acidosis probably accentuates metabolic bone disease.

PROBLEMS OF UNDETERMINED CAUSES

Intractable ascites is a puzzling and very rare complication in patients treated by maintenance haemodialysis, the aetiology and pathogenesis of which remain a mystery in most instances (82).

Pruritis is common and often is severe and unrelenting (83).

Psychiatric, emotional, and social problems are major complications in this population. Finally, many serious complications result from the use of inappropriate drugs and dosage levels in dialysis patients.
(vii) **MORTALITY IN PATIENTS ON HAEMODIALYSIS**

The average death rate in patients on long-term haemodialysis in many well established centres is estimated to be about 10 per cent per year (84). Prominent causes of death are cardiac disease, cerebrovascular disease and infections (85). Other causes of death have included respiratory disease, "kidney disease and uraemia", endocrine and metabolic diseases; complications of treatment and accidental death; diseases of digestive system and liver; Neuropsychiatric diseases, and neoplasms.

(viii) **HAEMODIALYSIS - THE AFRICAN SITUATION**

Regular haemodialysis programmes are expensive and might drain a disproportionately high portion of the health budget in countries with limited resources. This is probably the major reason why such centres have not found place in most developing countries (86).

There is, however, evidence that haemodialysis, in one form or another, has been practised as a form of therapy in Egypt since 1966 (87), in the Sudan since 1974 (88) and in Kenya since 1973 (89, 90).
11. MATERIALS AND METHODS

RETROSPECTIVE STUDY

The records of all patients started on haemodialysis at Kenyatta National Hospital, between July 1973 and June 1982, were analysed retrospectively. The total of 57 patients included 31 with acute renal failure and 26 with chronic renal failure.

During that period, haemodialysis was used in three categories of patients:

(a) those with acute renal failure who were expected to recover soon with supportive treatment.
(b) those with stable chronic renal failure, who destabilised after developing an acute episode precipitating rapidly increasing uraemia.
(c) those patients whose renal disease was uncertain and awaited confirmation of diagnosis.

Thus haemodialysis, as a form of replacement therapy for chronic uraemia, was never envisaged at that time.
Patients were dialysed three times weekly for five to seven hours, following a variable period (four to seven) of daily dialysis. The MC-20 coil dialyser was used throughout the period. The water supply used was tap water from the city supply system. There was no additional treatment. Batch production of dialysate requiring the mixing of dry chemicals with water in a container large enough to provide for the entire treatment was in use then. Photograph 4 shows the haemodialysis equipment used between July 1973 and June 1982.
The data on the patients thus treated are analysed with respect to:

(a) Age and sex

(b) Renal failure syndrome necessitating institution of haemodialysis therapy.

(c) Primary cause of renal failure syndrome.

(d) Clinical features at the onset of haemodialysis therapy.

(e) Some biochemical parameters at the onset of haemodialysis therapy.

(f) Outcome of haemodialysis therapy.
Photograph 4: Haemodialysis equipment used at the Kenyatta National Hospital between July 1973 and June 1982.
PROSPECTIVE STUDY

The author was actively involved in the management of patients with renal failure syndromes in the period between August 1984 and August 1985.

(1) PATIENTS: Between August 1984 and August 1985, forty two patients were started on haemodialysis therapy. These included twenty with acute renal failure and twenty two with chronic renal failure. All patients with acute renal failure were eligible for haemodialysis. The selection of patients with chronic renal failure for maintenance haemodialysis was the sole responsibility of the hospital nephrologists. The guidelines outlined in Appendix I were used in the selection.

Before the start of dialysis, the following data were obtained from the patients.

(a) Age and sex

(b) Renal failure syndrome

(c) The duration of the illness (renal failure) that is, the duration between the time at which the patient first developed symptoms of renal failure and the time of initiation of dialysis.

(e) Laboratory data viz:

(i) serum creatinine

(ii) Blood urea nitrogen

(iii) serum potassium and sodium levels
(iv) serum calcium and inorganic phosphate levels where indicated.

(v) creatinine clearance

(vi) full haemogram

(vii) urinalysis

(viii) others:
- Chest X-rays
- Electrocardiograms and Echocardiograms
- Renal ultrasounds
- Intravenous Urograms (where possible)

Once dialysis was started, the predialysis serum potassium and sodium and the blood urea nitrogen were done at every dialysis. The post-dialysis urea and electrolytes and other investigations were done as required.

The short-term complications and the outcome of dialytic therapy were looked into.

(2) ARTERIOVENOUS SHUNTS: Once the decision to start a patient on haemodialysis was made, a limb arteriovenous shunt (Scribner-Quinton type) was fashioned. This was done by urological surgeons, nephrologist or senior house officers in medicine and paediatrics going through their rotation in nephrology.

During the study period, complications arising by virtue of the presence of the shunts were looked into. Thus,

(a) The clotting of a shunt was noted any time it occurred.

(b) Any significant bleeding from the shunt site or following a disconnection of the shunt was noted.

(c) Swabs for cultures were taken from the shunt site in the second week after placement and at any time there-
after when there were signs of acute inflammation at the shunt site, such as pain, tenderness, and redness ("shininess") with or without pus formation.

The cannula replacement rate following complications was worked out. Photograph 5 shows an arteriovenous shunt in situ in one of the patients dialysed during the prospective study period.

(3) DIALYSIS EQUIPMENT: In the prospective study period the Gambro (R) machines were used exclusively. These were equipped with monitors for conductivity and temperature of dialysate, blood leaks, arterial and venous pressures, tubing collapse and air bubbles. The tubing and dialysers were for single use. For all the forty two patients except two, the Gambro Lundia plate dialysers (1.25 m² surface area, 11.5 microns membrane thickness) was used. One patient, 9 years old, required the use of a Gambro Lundia minor dialyser (0.51 m² surface area, 13.5 microns membrane thickness) and the other, a grossly muscular man, required the use of a Gambro Lundia major dialyser (1.7 m² surface area, 11.5 microns membrane thickness). Photograph 6 shows a patient on haemodialysis.

(4) WATER TREATMENT AND DIALYSATE SUPPLY: In the prospective study period, the water used for dialysis was softened, sedimented and filtered then reverse osmosed before being pumped to the continuous proportioning system which used a fixed proportioning pump to mix liquid concentrate with the water to produce the final dialysate as required, generally in 1/34 proportion. The dialysate solute concentration for all patients was sodium, 133.0 mmol/l; potassium, 3.0 mmol/l; calcium
1.75 mmol/l; magnesium, 1.0 mmol/l; chloride, 108.5 mmol/l; Acetate, 38.0 mmol/l; and glucose, 3.0 g/l. Photograph 7 shows part of the reverse osmosis equipment at the Kenyatta National Hospital.

(5) **THE DIALYSIS PROCEDURE:** All patients with acute renal failure underwent an initial four to five days daily dialysis and thereafter thrice-weekly, four hour dialyses until recovery or death. The patients with chronic renal failure underwent thrice weekly, four hour dialyses. The initial one or two dialyses, in all patients, were of short duration (two or three hours) to avoid dialysis disequilibrium. Emergency dialysis was carried out mostly on patients who developed severe pulmonary oedema in the interdialytic period.

The blood flow rate during most of the dialyses has been 150 to 200 mls/min. The transmembrane pressure (ultrafiltration or hydrostatic pressure) has been personalised according to individual patient need, that is, the degree of fluid overload. In all the dialyses heparin infusion at a rate of 500 units/hr has been used, except on one patient who required 1000 units/hr, to prevent clotting of blood in the tubing. In most of the cases the bedside whole blood clotting time has been relied upon for adequate heparinisation.

All dialyses, except emergency dialyses, were carried out during the day, mostly in the mornings. The dialyses were all nurse-attended, with the doctors coming in as necessary, following the review of patients before the start of each dialysis.
Photograph 5: An arteriovenous shunt in situ in one of the patients dialysed during the prospective study.

The Shunt has been in situ for 20 weeks, required declotting only once.
Photograph 7: Part of the reverse osmosis equipment for water treatment at the Kenyatta National Hospital dialysis Unit.
IV. RESULTS

RETROSPECTIVE STUDY

A total of fifty seven patients were haemodialysed between July 1973 and June 1982. Of the 57 who were haemodialysed 26 (45.6%) were females and 31 (54.4%) were males. Their ages were between 9 and 50 years with a mean of 29.6 years (Fig. 3). Thirty one patients (54.4%) had acute renal failure, eighteen (31.6%) chronic renal failure and eight (14%) had acute on chronic renal failure (Fig. 4). Fig. 5 shows the number of patients dialysed during each of the years beginning from July 1973.

Causes of renal failure in patients who underwent haemodialysis (July 1973 - June 1982) - Tables 1 and 2

<table>
<thead>
<tr>
<th>Table I:</th>
<th>ACUTE RENAL FAILURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary cause</td>
<td>Number</td>
</tr>
<tr>
<td>Disseminated Intravascular coagulation, sepsis and haemorrhage</td>
<td>10</td>
</tr>
<tr>
<td>Antepartum/postpartum haemorrhage</td>
<td>6</td>
</tr>
<tr>
<td>Surgery with haemorrhage</td>
<td>4</td>
</tr>
<tr>
<td>Mismatched transfusion</td>
<td>3</td>
</tr>
<tr>
<td>Multiple injuries and haemorrhage</td>
<td>3</td>
</tr>
<tr>
<td>Acute glomerulonephritis</td>
<td>2</td>
</tr>
<tr>
<td>Not known</td>
<td>2</td>
</tr>
<tr>
<td>Haemolytic Uraemic syndrome</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>31</td>
</tr>
</tbody>
</table>
Fig. 3: Age and Sex distribution of the patients who underwent haemodialysis between July 1973 and June 1982 (Retrospective period).
Fig. 4: The distribution of patients who have undergone haemodialysis by syndromes.

**NUMBER OF PATIENTS**

<table>
<thead>
<tr>
<th>SYNDROME</th>
<th>0</th>
<th>10</th>
<th>20</th>
<th>30</th>
<th>40</th>
<th>50</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARF</td>
<td></td>
<td>31</td>
<td>18</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRF</td>
<td></td>
<td></td>
<td></td>
<td>35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A on CRF</td>
<td></td>
<td>8</td>
<td>13</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ARF - Acute renal failure  
CRF - Chronic renal failure  
A on CRF - Acute on chronic renal failure
Fig. 5: Number of patients dialysed during each year beginning from July, 1973.
Table 2:

<table>
<thead>
<tr>
<th>Presumed cause(s)</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic glomerulonephritis</td>
<td>12+</td>
<td>46.2%</td>
</tr>
<tr>
<td>Not known</td>
<td>6</td>
<td>23.1%</td>
</tr>
<tr>
<td>Hypertensive nephrosclerosis</td>
<td>4</td>
<td>15.4%</td>
</tr>
<tr>
<td>Obstructive uropathy</td>
<td>2</td>
<td>7.7%</td>
</tr>
<tr>
<td>Hypoplasia and nephrosclerosis</td>
<td>1</td>
<td>3.8%</td>
</tr>
<tr>
<td>Pyelonephritis</td>
<td>1*</td>
<td>3.8%</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>26</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

* Pre- and Post-mortem histology in 8

- Intravenous pyelogram diagnosis

Clinical features in renal failure patients (July 1973 to June 1982) at the onset of haemodialysis

Most of the patients who were started on haemodialysis in the period between July 1973 and June 1982 were very ill. The frequency of some of the symptoms and signs are depicted in table 3 and 4.
### RETROSPECTIVE

(JULY 1973 – JUNE 1982)

<table>
<thead>
<tr>
<th>SYMPTOMS</th>
<th>% (NUMBER)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oligoanuria</td>
<td>100% (31)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>79% (24)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>72% (22)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>64% (20)</td>
</tr>
<tr>
<td>Nausea</td>
<td>63% (19)</td>
</tr>
<tr>
<td>Swelling of body</td>
<td>32% (10)</td>
</tr>
<tr>
<td>Cough</td>
<td>21% (6)</td>
</tr>
<tr>
<td>Headache</td>
<td>13% (4)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>10% (3)</td>
</tr>
<tr>
<td>Bleeding</td>
<td>10% (3)</td>
</tr>
<tr>
<td>Convulsions</td>
<td>6% (2)</td>
</tr>
<tr>
<td>Coma</td>
<td>3% (1)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>0% (0)</td>
</tr>
<tr>
<td>Pruritis</td>
<td>0% (0)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPTOMS</th>
<th>% (NUMBER)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dizziness</td>
<td>100% (18)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>94% (17)</td>
</tr>
<tr>
<td>Nausea</td>
<td>89% (16)</td>
</tr>
<tr>
<td>Headache</td>
<td>72% (13)</td>
</tr>
<tr>
<td>Bleeding</td>
<td>67% (12)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>56% (10)</td>
</tr>
<tr>
<td>Pruritis</td>
<td>56% (10)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>50% (9)</td>
</tr>
<tr>
<td>Swelling of body</td>
<td>50% (9)</td>
</tr>
<tr>
<td>Convulsions</td>
<td>28% (5)</td>
</tr>
<tr>
<td>Coma</td>
<td>28% (5)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>11% (2)</td>
</tr>
<tr>
<td>Oligoanuria</td>
<td>0% (0)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SYMPTOMS</th>
<th>% (NUMBER)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bleeding</td>
<td>100% (8)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>100% (8)</td>
</tr>
<tr>
<td>Oligoanuria</td>
<td>100% (8)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>88% (7)</td>
</tr>
<tr>
<td>Nausea</td>
<td>88% (7)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>88% (7)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>67% (6)</td>
</tr>
<tr>
<td>Cough</td>
<td>63% (5)</td>
</tr>
<tr>
<td>Headache</td>
<td>63% (5)</td>
</tr>
<tr>
<td>Pruritis</td>
<td>63% (5)</td>
</tr>
<tr>
<td>Swelling of body</td>
<td>50% (4)</td>
</tr>
<tr>
<td>Coma</td>
<td>38% (3)</td>
</tr>
<tr>
<td>Convulsions</td>
<td>25% (2)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>0% (0)</td>
</tr>
</tbody>
</table>

Table 3: The frequency of some symptoms in renal failure patients at the onset of haemodialysis.
### Table 4: The frequency of some clinical features in renal failure patients at the onset of haemodialysis

<table>
<thead>
<tr>
<th>Signs</th>
<th>% (Number)</th>
<th>Signs</th>
<th>% (Number)</th>
<th>Signs</th>
<th>% (Number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moribund</td>
<td>48% (15)</td>
<td>Pallor</td>
<td>100% (18)</td>
<td>Pallor</td>
<td>100% (8)</td>
</tr>
<tr>
<td>Stupor or coma</td>
<td>42% (13)</td>
<td>Hypertension</td>
<td>89% (16)</td>
<td>Hypertension</td>
<td>100% (8)</td>
</tr>
<tr>
<td>Pallor</td>
<td>39% (12)</td>
<td>Moribund</td>
<td>78% (15)</td>
<td>Poor Nutrition</td>
<td>100%</td>
</tr>
<tr>
<td>Infection</td>
<td>32% (10)</td>
<td>Stupor or coma</td>
<td>78% (15)</td>
<td>Moribund</td>
<td>88% (7)</td>
</tr>
<tr>
<td>Bleeding</td>
<td>23% (7)</td>
<td>Bleeding</td>
<td>56% (10)</td>
<td>Stupor or coma</td>
<td>88% (7)</td>
</tr>
<tr>
<td>Oedema</td>
<td>6% (2)</td>
<td>Poor Nutrition</td>
<td>56% (10)</td>
<td>Bleeding</td>
<td>75% (6)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3% (1)</td>
<td>Pericarditis</td>
<td>33% (6)</td>
<td>Bone tenderness</td>
<td>63% (5)</td>
</tr>
<tr>
<td>Poor Nutrition</td>
<td>3% (1)</td>
<td>Bone tenderness</td>
<td>28% (5)</td>
<td>Pulmonary Oedema</td>
<td>50% (4)</td>
</tr>
<tr>
<td>Pericarditis</td>
<td>0% (0)</td>
<td>Pulmonary Oedema</td>
<td>22% (4)</td>
<td>Heart failure</td>
<td>50% (4)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>0% (0)</td>
<td>Heart failure</td>
<td>22% (4)</td>
<td>Oedema</td>
<td>50% (4)</td>
</tr>
<tr>
<td>Pulmonary Oedema</td>
<td>0% (0)</td>
<td>Infection</td>
<td>22% (4)</td>
<td>Oedema</td>
<td>38% (3)</td>
</tr>
<tr>
<td>Pleural effusion</td>
<td>0% (0)</td>
<td>Oedema</td>
<td>22% (4)</td>
<td>Infection</td>
<td>25% (2)</td>
</tr>
<tr>
<td>Ascites</td>
<td>0% (0)</td>
<td>Pleural effusion</td>
<td>17% (3)</td>
<td>Ascites</td>
<td>13% (1)</td>
</tr>
<tr>
<td>Bone tenderness</td>
<td>0% (0)</td>
<td>Ascites</td>
<td>11% (2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- 4A: ARF
- 4B: CRF
- 4C: A on CRF
The biochemical parameters for patients with acute renal failure are shown in Table 5. The mean potassium levels were 5.6 mmol/L (Range 3.4 - 8.4 mmol/L), blood urea nitrogen 55.5 mmol/L (Range 22 - 105 mmol/L) and serum creatinine 417 mmol/L (Range 130 - 1000 mmol/L). For chronic renal failure patients (Table 6) the corresponding figures for serum potassium, blood urea nitrogen and serum creatinine were 4.1 mmol/L (2.8 - 6.2 mmol/L), 59.3 mmol/L (26 - 100 mmol/L) and 650 (215 - 1300 mmol/L).

KEY TO TABLE 5 AND 6

Na+ — Sodium
K+ — Potassium
Cl− — Chloride
\( \text{PO}_4^{3-} \) — inorganic phosphate
Ca2+ — Calcium
HCO\(^{-3} \) — bicarbonate
BUN — Blood urea nitrogen
Cr — creatinine
Table 5: Pre-Dialysis Biochemical Parameters in Acute Renal Failure Patients (July 1973 to June 1982)

<table>
<thead>
<tr>
<th>Patient</th>
<th>Na+</th>
<th>K+</th>
<th>Cl⁻</th>
<th>PO₄³⁻</th>
<th>Ca²⁺</th>
<th>HCO₃⁻</th>
<th>pH</th>
<th>BUN</th>
<th>Cr (mcmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I . A</td>
<td>146</td>
<td>5.8</td>
<td>105</td>
<td>1.6</td>
<td>2.5</td>
<td>15</td>
<td>7.32</td>
<td>48</td>
<td>266</td>
</tr>
<tr>
<td>V . S</td>
<td>132</td>
<td>5.6</td>
<td>100</td>
<td>1.6</td>
<td>2.3</td>
<td>11</td>
<td>7.20</td>
<td>105</td>
<td>1000</td>
</tr>
<tr>
<td>E . N</td>
<td>140</td>
<td>4.2</td>
<td>96</td>
<td>1.4</td>
<td>2.3</td>
<td>19</td>
<td>7.30</td>
<td>87</td>
<td>650</td>
</tr>
<tr>
<td>J . N</td>
<td>128</td>
<td>3.5</td>
<td>102</td>
<td>1.2</td>
<td>2.0</td>
<td>17</td>
<td>7.27</td>
<td>62</td>
<td>500</td>
</tr>
<tr>
<td>J . G</td>
<td>155</td>
<td>3.4</td>
<td>98</td>
<td>1.7</td>
<td>2.1</td>
<td>15</td>
<td>7.28</td>
<td>44</td>
<td>208</td>
</tr>
<tr>
<td>K . G</td>
<td>130</td>
<td>6.0</td>
<td>100</td>
<td>1.0</td>
<td>1.9</td>
<td>16</td>
<td>7.27</td>
<td>39</td>
<td>200</td>
</tr>
<tr>
<td>A . E</td>
<td>130</td>
<td>5.0</td>
<td>94</td>
<td>0.8</td>
<td>2.4</td>
<td>20</td>
<td>7.30</td>
<td>36</td>
<td>167</td>
</tr>
<tr>
<td>S . N</td>
<td>142</td>
<td>4.6</td>
<td>103</td>
<td>1.2</td>
<td>1.7</td>
<td>20</td>
<td>7.33</td>
<td>50</td>
<td>289</td>
</tr>
<tr>
<td>R . N</td>
<td>136</td>
<td>4.5</td>
<td>106</td>
<td>1.5</td>
<td>1.8</td>
<td>14</td>
<td>7.26</td>
<td>67</td>
<td>500</td>
</tr>
<tr>
<td>M . K</td>
<td>150</td>
<td>6.7</td>
<td>105</td>
<td>1.1</td>
<td>1.5</td>
<td>21</td>
<td>7.38</td>
<td>54</td>
<td>350</td>
</tr>
<tr>
<td>G . O</td>
<td>128</td>
<td>3.6</td>
<td>95</td>
<td>1.8</td>
<td>2.0</td>
<td>16</td>
<td>7.28</td>
<td>60</td>
<td>482</td>
</tr>
<tr>
<td>M . M</td>
<td>144</td>
<td>7.2</td>
<td>101</td>
<td>0.9</td>
<td>1.6</td>
<td>11</td>
<td>7.25</td>
<td>74</td>
<td>591</td>
</tr>
<tr>
<td>S . M</td>
<td>150</td>
<td>6.4</td>
<td>98</td>
<td>1.4</td>
<td>2.4</td>
<td>15</td>
<td>7.27</td>
<td>49</td>
<td>380</td>
</tr>
<tr>
<td>C . I</td>
<td>134</td>
<td>5.4</td>
<td>99</td>
<td>1.4</td>
<td>2.0</td>
<td>20</td>
<td>7.32</td>
<td>55</td>
<td>400</td>
</tr>
<tr>
<td>C . R</td>
<td>136</td>
<td>8.0</td>
<td>100</td>
<td>0.9</td>
<td>1.8</td>
<td>16</td>
<td>7.30</td>
<td>63</td>
<td>567</td>
</tr>
<tr>
<td>S . A</td>
<td>130</td>
<td>4.0</td>
<td>100</td>
<td>1.3</td>
<td>2.1</td>
<td>18</td>
<td>7.32</td>
<td>50</td>
<td>300</td>
</tr>
<tr>
<td>R . M</td>
<td>142</td>
<td>4.0</td>
<td>104</td>
<td>1.6</td>
<td>2.7</td>
<td>22</td>
<td>7.36</td>
<td>41</td>
<td>250</td>
</tr>
<tr>
<td>J . O</td>
<td>150</td>
<td>7.3</td>
<td>97</td>
<td>1.7</td>
<td>1.5</td>
<td>10</td>
<td>7.22</td>
<td>89</td>
<td>700</td>
</tr>
<tr>
<td>E . K</td>
<td>146</td>
<td>6.6</td>
<td>92</td>
<td>1.0</td>
<td>1.7</td>
<td>20</td>
<td>7.36</td>
<td>42</td>
<td>280</td>
</tr>
<tr>
<td>J . A</td>
<td>130</td>
<td>5.7</td>
<td>106</td>
<td>1.4</td>
<td>2.0</td>
<td>14</td>
<td>7.28</td>
<td>70</td>
<td>574</td>
</tr>
<tr>
<td>M . F</td>
<td>126</td>
<td>3.7</td>
<td>100</td>
<td>1.2</td>
<td>1.9</td>
<td>16</td>
<td>7.28</td>
<td>66</td>
<td>600</td>
</tr>
<tr>
<td>S . A</td>
<td>142</td>
<td>3.6</td>
<td>94</td>
<td>2.0</td>
<td>2.1</td>
<td>17</td>
<td>7.30</td>
<td>49</td>
<td>293</td>
</tr>
<tr>
<td>A . K</td>
<td>150</td>
<td>8.4</td>
<td>99</td>
<td>0.6</td>
<td>2.2</td>
<td>15</td>
<td>7.26</td>
<td>52</td>
<td>340</td>
</tr>
<tr>
<td>B . M</td>
<td>150</td>
<td>5.8</td>
<td>98</td>
<td>1.1</td>
<td>2.4</td>
<td>18</td>
<td>7.32</td>
<td>39</td>
<td>320</td>
</tr>
<tr>
<td>M . S</td>
<td>134</td>
<td>6.5</td>
<td>110</td>
<td>1.4</td>
<td>1.8</td>
<td>24</td>
<td>7.40</td>
<td>26</td>
<td>130</td>
</tr>
<tr>
<td>W . J</td>
<td>128</td>
<td>7.2</td>
<td>101</td>
<td>0.9</td>
<td>2.0</td>
<td>19</td>
<td>7.36</td>
<td>51</td>
<td>400</td>
</tr>
<tr>
<td>M . L</td>
<td>142</td>
<td>6.2</td>
<td>93</td>
<td>1.3</td>
<td>2.4</td>
<td>16</td>
<td>7.30</td>
<td>58</td>
<td>326</td>
</tr>
<tr>
<td>W . H</td>
<td>140</td>
<td>8.0</td>
<td>103</td>
<td>1.3</td>
<td>2.1</td>
<td>20</td>
<td>7.34</td>
<td>32</td>
<td>283</td>
</tr>
<tr>
<td>O . O</td>
<td>136</td>
<td>3.5</td>
<td>96</td>
<td>1.8</td>
<td>1.6</td>
<td>21</td>
<td>7.36</td>
<td>22</td>
<td>160</td>
</tr>
<tr>
<td>J . M</td>
<td>150</td>
<td>4.1</td>
<td>105</td>
<td>1.8</td>
<td>1.8</td>
<td>15</td>
<td>7.28</td>
<td>61</td>
<td>540</td>
</tr>
<tr>
<td>A . C</td>
<td>148</td>
<td>6.0</td>
<td>94</td>
<td>1.0</td>
<td>2.0</td>
<td>12</td>
<td>7.28</td>
<td>100</td>
<td>874</td>
</tr>
</tbody>
</table>
Table 6:

PRE-DIALYSIS BIOCHEMICAL PARAMETERS IN CHRONIC RENAL FAILURE PATIENTS
(JULY 1973 TO JUNE 1982)

<table>
<thead>
<tr>
<th>Patient</th>
<th>Na⁺</th>
<th>K⁺</th>
<th>Cl⁻</th>
<th>Ca²⁺</th>
<th>HCO₃⁻</th>
<th>PH</th>
<th>BUN</th>
<th>Cr(mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>W. W</td>
<td>130</td>
<td>3.0</td>
<td>96</td>
<td>2.0</td>
<td>1.1</td>
<td>12</td>
<td>7.23</td>
<td>41</td>
</tr>
<tr>
<td>J. A</td>
<td>128</td>
<td>3.0</td>
<td>105</td>
<td>1.8</td>
<td>1.4</td>
<td>18</td>
<td>7.30</td>
<td>45</td>
</tr>
<tr>
<td>D. A</td>
<td>132</td>
<td>3.4</td>
<td>98</td>
<td>2.2</td>
<td>2.0</td>
<td>22</td>
<td>7.38</td>
<td>55</td>
</tr>
<tr>
<td>R. B</td>
<td>126</td>
<td>3.6</td>
<td>99</td>
<td>1.6</td>
<td>1.6</td>
<td>16</td>
<td>7.34</td>
<td>87</td>
</tr>
<tr>
<td>T. S</td>
<td>132</td>
<td>4.1</td>
<td>98</td>
<td>1.5</td>
<td>1.5</td>
<td>10</td>
<td>7.21</td>
<td>90</td>
</tr>
<tr>
<td>M. G</td>
<td>130</td>
<td>3.4</td>
<td>96</td>
<td>1.6</td>
<td>2.5</td>
<td>16</td>
<td>7.26</td>
<td>26</td>
</tr>
<tr>
<td>O. P</td>
<td>130</td>
<td>4.5</td>
<td>100</td>
<td>1.7</td>
<td>2.0</td>
<td>15</td>
<td>7.28</td>
<td>36</td>
</tr>
<tr>
<td>K. W</td>
<td>128</td>
<td>4.4</td>
<td>95</td>
<td>3.0</td>
<td>1.2</td>
<td>18</td>
<td>7.34</td>
<td>60</td>
</tr>
<tr>
<td>A. H</td>
<td>134</td>
<td>4.3</td>
<td>94</td>
<td>1.9</td>
<td>2.7</td>
<td>20</td>
<td>7.36</td>
<td>81</td>
</tr>
<tr>
<td>J. A</td>
<td>122</td>
<td>3.6</td>
<td>98</td>
<td>2.4</td>
<td>2.1</td>
<td>17</td>
<td>7.32</td>
<td>72</td>
</tr>
<tr>
<td>R. W</td>
<td>136</td>
<td>3.8</td>
<td>97</td>
<td>3.1</td>
<td>1.8</td>
<td>16</td>
<td>7.34</td>
<td>80</td>
</tr>
<tr>
<td>K. S</td>
<td>130</td>
<td>4.5</td>
<td>99</td>
<td>2.2</td>
<td>2.0</td>
<td>19</td>
<td>7.30</td>
<td>45</td>
</tr>
<tr>
<td>M. O</td>
<td>140</td>
<td>5.0</td>
<td>90</td>
<td>2.6</td>
<td>1.9</td>
<td>20</td>
<td>7.38</td>
<td>86</td>
</tr>
<tr>
<td>W. M</td>
<td>138</td>
<td>5.5</td>
<td>106</td>
<td>2.1</td>
<td>2.5</td>
<td>15</td>
<td>7.28</td>
<td>45</td>
</tr>
<tr>
<td>N. R</td>
<td>130</td>
<td>4.2</td>
<td>102</td>
<td>1.7</td>
<td>2.0</td>
<td>23</td>
<td>7.38</td>
<td>47</td>
</tr>
<tr>
<td>K. I</td>
<td>128</td>
<td>3.6</td>
<td>94</td>
<td>1.5</td>
<td>1.2</td>
<td>19</td>
<td>7.26</td>
<td>39</td>
</tr>
<tr>
<td>M. W</td>
<td>134</td>
<td>6.0</td>
<td>102</td>
<td>1.8</td>
<td>1.0</td>
<td>10</td>
<td>7.22</td>
<td>57</td>
</tr>
<tr>
<td>C. S</td>
<td>136</td>
<td>4.4</td>
<td>100</td>
<td>2.0</td>
<td>1.0</td>
<td>15</td>
<td>7.24</td>
<td>61</td>
</tr>
<tr>
<td>M. W</td>
<td>134</td>
<td>3.8</td>
<td>99</td>
<td>2.0</td>
<td>2.3</td>
<td>14</td>
<td>7.24</td>
<td>100</td>
</tr>
<tr>
<td>K. C</td>
<td>130</td>
<td>6.2</td>
<td>95</td>
<td>2.4</td>
<td>0.8</td>
<td>11</td>
<td>7.21</td>
<td>96</td>
</tr>
<tr>
<td>M. M</td>
<td>128</td>
<td>2.8</td>
<td>102</td>
<td>1.8</td>
<td>2.0</td>
<td>22</td>
<td>7.38</td>
<td>54</td>
</tr>
<tr>
<td>R. K</td>
<td>142</td>
<td>4.6</td>
<td>99</td>
<td>2.0</td>
<td>1.1</td>
<td>20</td>
<td>7.36</td>
<td>65</td>
</tr>
<tr>
<td>O. H</td>
<td>130</td>
<td>5.0</td>
<td>98</td>
<td>2.8</td>
<td>1.6</td>
<td>17</td>
<td>7.30</td>
<td>74</td>
</tr>
<tr>
<td>A. G</td>
<td>144</td>
<td>5.0</td>
<td>99</td>
<td>1.3</td>
<td>2.0</td>
<td>19</td>
<td>7.36</td>
<td>56</td>
</tr>
<tr>
<td>P. A</td>
<td>130</td>
<td>4.8</td>
<td>92</td>
<td>2.6</td>
<td>1.4</td>
<td>19</td>
<td>7.34</td>
<td>43</td>
</tr>
</tbody>
</table>
Outcome of haemodialysis

In the period from July 1973 to June 1982 the patients were haemodialysed for periods varying from 1 to 56 days with a mean duration of 10 days. The number of dialyses per patient varied between 1 and 30, mean 8.

Of the 31 patients with acute renal failure dialysed, 61.3% died, the rest recovered and were discharged for follow up. 31.6% of the deaths were considered due to uraemia, the deaths could not be related to any biochemical aberration, 47.3% due to the primary cause of acute renal failure, 15.8% due to dialysis disequilibrium and 5.3% due to haemorrhage related to heparin infusion during haemodialysis.

55.6% of the patients with chronic renal failure on haemodialysis died, the rest were discharged to the home district hospitals for terminal care after confirmation of diagnosis. Of those who died, 50% were due to uraemia, 40% due to dialysis disequilibrium and 10% due to septicaemia.

Of the patients with acute or chronic failure 50% died, the rest gained their residual renal function and were discharged. 50% of the deaths were due to uraemia, 25% due to dialysis disequilibrium and in the rest, the cause of death was not established.

The clinical and biochemical response to haemodialysis in these patients was difficult to analyse due to the limited numbers of dialyses and lack of documentation.
PROSPECTIVE STUDY

Forty two patients have been haemodialysed in the one year period between August 1984 and August 1985. Of these 54.8% were females and 45.2% were males. Their ages ranged between 9 and 56 years with a mean of 30.2 years (Fig. 6). 47.6% of the patients had acute renal failure, 40.5% had chronic renal failure and 11.9% had acute on chronic renal failure.

Tables 7 and 8 show the frequency of some symptoms and signs at the onset of haemodialysis in the prospective period.

Table 9 shows a summary of experience with acute renal failure patients on haemodialysis. Of the 20 patients with acute renal failure dialysed, 30% died. In all cases the cause of death was unrelated to the haemodialysis procedure (Table 10).

In the acute renal failure patients, the average predialysis blood urea nitrogen, serum potassium and serum creatinine were 32.5 mmol/L (range 19 to 64.5) 6.2 (range 4.0 - 8.0) and 345 mcml/L (range 133 to 640) respectively.
Fig. 6: Age and Sex distribution of the patients who underwent haemodialysis between August, 1984 and August, 1985 (prospective period).
### Table 7: The frequency of some symptoms in renal failure patients at the onset of haemodialysis.

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>7A: ARF % (Number)</th>
<th>7B: CRF % (Number)</th>
<th>7C: A on CRF % (Number)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oligoanuria</td>
<td>85% (17)</td>
<td>Anorexia 100% (17)</td>
<td>Anorexia 100% (5)</td>
</tr>
<tr>
<td>Anorexia</td>
<td>60% (12)</td>
<td>Nausea 100% (17)</td>
<td>Nausea 100% (5)</td>
</tr>
<tr>
<td>Dyspnoea</td>
<td>60% (12)</td>
<td>Headache 88% (18)</td>
<td>Headache 100% (5)</td>
</tr>
<tr>
<td>Nausea</td>
<td>50% (10)</td>
<td>Dizziness 71% (12)</td>
<td>Dizziness 100% (5)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>50% (10)</td>
<td>Pruritis 59% (10)</td>
<td>Oligoanuria 100% (5)</td>
</tr>
<tr>
<td>Bleeding</td>
<td>10% (2)</td>
<td>Bleeding 59% (10)</td>
<td>Dyspnoea 100% (5)</td>
</tr>
<tr>
<td>Swelling of body</td>
<td>10% (2)</td>
<td>Dyspnoea 47% (8)</td>
<td>Bleeding 80% (4)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>5% (1)</td>
<td>Vomiting 41% (7)</td>
<td>Pruritis 60% (3)</td>
</tr>
<tr>
<td>Headache</td>
<td>5% (1)</td>
<td>Chest pain 18% (3)</td>
<td>Swelling of body 60% (3)</td>
</tr>
<tr>
<td>Chest pain</td>
<td>0% (0)</td>
<td>Swelling of body 18% (3)</td>
<td>Vomiting 60% (3)</td>
</tr>
<tr>
<td>Cough</td>
<td>0% (0)</td>
<td>Convulsions 12% (2)</td>
<td>Coma 40% (2)</td>
</tr>
<tr>
<td>Convulsions</td>
<td>0% (0)</td>
<td>Cough 6% (1)</td>
<td>Convulsions 40% (2)</td>
</tr>
<tr>
<td>Coma</td>
<td>0% (0)</td>
<td>Coma 6% (1)</td>
<td>Chest pain 40% (2)</td>
</tr>
<tr>
<td>Pruritis</td>
<td>0% (0)</td>
<td>Oligoanuria 0% (0)</td>
<td>Cough 0% (0)</td>
</tr>
</tbody>
</table>
Table 8: The frequency of some clinical features in renal failure patients at the onset of haemodialysis.
### TABLE 9:

#### SUMMARY OF EXPERIENCE - ACUTE RENAL FAILURE PATIENTS ON HAEMODIALYSIS

<table>
<thead>
<tr>
<th>PATIENT</th>
<th>AGE (YEARS)</th>
<th>SEX</th>
<th>CAUSE OF RENAL FAILURE</th>
<th>NUMBER OF DIALYSES</th>
<th>OUTCOME</th>
</tr>
</thead>
<tbody>
<tr>
<td>L . Z</td>
<td>18</td>
<td>F</td>
<td>DIC, Haemorrhage</td>
<td>5</td>
<td>Dead</td>
</tr>
<tr>
<td>C . K</td>
<td>17</td>
<td>F</td>
<td>Haemorrhage (surgical)</td>
<td>2</td>
<td>Dead</td>
</tr>
<tr>
<td>M . G</td>
<td>26</td>
<td>F</td>
<td>DIC, Haemorrhage</td>
<td>1</td>
<td>Living</td>
</tr>
<tr>
<td>H . W</td>
<td>30</td>
<td>F</td>
<td>Haemorrhage (hydatidiform mole)</td>
<td>4</td>
<td>Living</td>
</tr>
<tr>
<td>F . K</td>
<td>30</td>
<td>F</td>
<td>Haemorrhage (surgical)</td>
<td>15</td>
<td>Living</td>
</tr>
<tr>
<td>J . N</td>
<td>37</td>
<td>F</td>
<td>Haemorrhage (DIC)</td>
<td>6</td>
<td>Living</td>
</tr>
<tr>
<td>M . M</td>
<td>28</td>
<td>F</td>
<td>DIC Haemorrhage</td>
<td>6</td>
<td>Living</td>
</tr>
<tr>
<td>F . M</td>
<td>28</td>
<td>F</td>
<td>Haemorrhage (DIC)</td>
<td>4</td>
<td>Living</td>
</tr>
<tr>
<td>M . W</td>
<td>56</td>
<td>F</td>
<td>Mismatched Transfusion</td>
<td>2</td>
<td>Living</td>
</tr>
<tr>
<td>F . A</td>
<td>30</td>
<td>F</td>
<td>Obstruction (uterine fibroids)</td>
<td>4</td>
<td>Living</td>
</tr>
<tr>
<td>M . K</td>
<td>30</td>
<td>F</td>
<td>Obstruction (ovarian cancer)</td>
<td>4</td>
<td>Dead</td>
</tr>
<tr>
<td>M . N</td>
<td>35</td>
<td>F</td>
<td>Haemorrhage (Gastrointestinal)</td>
<td>5</td>
<td>Dead</td>
</tr>
<tr>
<td>N . W</td>
<td>35</td>
<td>M</td>
<td>Malaria (DIC, Haemorrhage)</td>
<td>5</td>
<td>Living</td>
</tr>
<tr>
<td>E . W</td>
<td>34</td>
<td>F</td>
<td>Haemorrhage (surgical)</td>
<td>5</td>
<td>Dead</td>
</tr>
<tr>
<td>S . W</td>
<td>27</td>
<td>F</td>
<td>Acute glomerulonephritis</td>
<td>5</td>
<td>Living</td>
</tr>
<tr>
<td>J . O</td>
<td>41</td>
<td>M</td>
<td>Cholera</td>
<td>16</td>
<td>Living</td>
</tr>
<tr>
<td>H . M</td>
<td>25</td>
<td>M</td>
<td>Cholera</td>
<td>2</td>
<td>Dead</td>
</tr>
<tr>
<td>J . W</td>
<td>27</td>
<td>F</td>
<td>Mismatched Transfusion</td>
<td>7</td>
<td>Living</td>
</tr>
<tr>
<td>S . K</td>
<td>33</td>
<td>F</td>
<td>Acute glomerulonephritis</td>
<td>4</td>
<td>Living</td>
</tr>
<tr>
<td>P . A</td>
<td>24</td>
<td>F</td>
<td>Haemorrhage (fibroids)</td>
<td>12</td>
<td>Living</td>
</tr>
<tr>
<td>PATIENT</td>
<td>SEX</td>
<td>AGE (YEARS)</td>
<td>NUMBER OF DIALYSES</td>
<td>CAUSE OF DEATH</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-----</td>
<td>-------------</td>
<td>---------------------</td>
<td>------------------------------------</td>
<td></td>
</tr>
<tr>
<td>L . Z</td>
<td>F</td>
<td>18</td>
<td>5</td>
<td>Haemorrhage, DIC (Diffuse)</td>
<td></td>
</tr>
<tr>
<td>C . K</td>
<td>F</td>
<td>17</td>
<td>2</td>
<td>Peritonitis Ovarian cancer</td>
<td></td>
</tr>
<tr>
<td>M . K</td>
<td>F</td>
<td>30</td>
<td>4</td>
<td>Uterine cancer</td>
<td></td>
</tr>
<tr>
<td>M . N</td>
<td>F</td>
<td>35</td>
<td>5</td>
<td>Haemorrhage (Gastro-intestinal)</td>
<td></td>
</tr>
<tr>
<td>E . W</td>
<td>F</td>
<td>34</td>
<td>5</td>
<td>Uraemia</td>
<td></td>
</tr>
<tr>
<td>H . M</td>
<td>M</td>
<td>25</td>
<td>2</td>
<td>Pulmonary Oedema</td>
<td></td>
</tr>
</tbody>
</table>
MAINTENANCE HAEMODIALYSIS FOR CHRONIC RENAL FAILURE

(a) The patients before the start of haemodialysis

Between August 1984 and August 1985, 22 patients with chronic renal failure were placed on maintenance haemodialysis. By August 1985 the total duration of dialysis was 170 patient-weeks. On the 24 August 1985 four patients were being dialysed in hospital, two had been transplanted, and sixteen had died (Table 11). There were 16 men and 6 women. At the beginning of treatment their ages ranged from 9 to 55 years, mean 25.4 years.

The frequency of symptoms and signs in these patients is summarised in tables 7 and 8. At the time maintenance dialysis was started six patients were in moribund condition, 8 patients were considered to have started treatment at the optimum time, and the remaining 8 patients were somewhere between these two groups.

Of the six moribund patients, three had had generalised fits, three had pericarditis and one severe gastrointestinal bleeding. One of this group was treated with peritoneal dialysis before maintenance haemodialysis was started. The 8 patients considered to have started maintenance haemodialysis at the optimum time had none of these complications; only one required peritoneal dialysis before haemodialysis was started. Of the remaining 8 patients whose clinical state was somewhere between the moribund and optimum group, two had pericarditis and two patients required peritoneal dialysis, and in both this was complicated by peritonitis. Pericarditis was diagnosed on clinical, electrocardiographic and echocardiographic evidence.
The endogenous creatinine-clearance on starting maintenance haemodialysis was less than 5 ml/min in 8 patients, and between 5 and 10 mls/min in four patients; no clearances were available in ten patients. The plasma creatinine levels prior to starting haemodialysis varied between 500 and 1800 mc mol/L, with a mean of 774 mc mol/L. In fourteen patients the plasma creatinine was between 500 and 1000 mc mol/L, in six patients between 1000 - 1500 mc mol/L and in two patients above 1500 mc mol/L. The blood urea nitrogen levels prior to starting haemodialysis varied between 20 and 116 mmol/L, with a mean of 58.5 mmol/L. In two patients the blood urea nitrogen was more than 100 mmol/L, in four patients between 60 and 100 mmol/L, and in sixteen patients between 20 and 60 mmol/L.

Chronic glomerulonephritis was the presumed (clinical and laboratory evidence) underlying renal disease in 13 patients, chronic obstructive uropathy in two, hypertensive nephrosclerosis in three, two patients had unilateral renal hypoplasia with nephrosclerosis in the other and in two patients no presumed renal disease was assigned. Malignant hypertension with papilloedema was present in three patients, severe hypertension without papilloedema in ten patients and moderate hypertension in nine patients.
<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (Years)</th>
<th>Sex</th>
<th>Presumptive Diagnosis</th>
<th>Weeks of Dialysis</th>
<th>Numbers of Dialysis</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>R . C</td>
<td>20</td>
<td>F</td>
<td>Chronic Glomerulonephritis</td>
<td>4</td>
<td>11</td>
<td>Dead</td>
</tr>
<tr>
<td>B . O</td>
<td>39</td>
<td>M</td>
<td>Hypertensive nephrosclerosis</td>
<td>0.5</td>
<td>2</td>
<td>Dead</td>
</tr>
<tr>
<td>M . W</td>
<td>12</td>
<td>F</td>
<td>Chronic Glomerulonephritis</td>
<td>19</td>
<td>55</td>
<td>Dead</td>
</tr>
<tr>
<td>L . K</td>
<td>18</td>
<td>F</td>
<td>Hypertensive nephrosclerosis</td>
<td>4</td>
<td>12</td>
<td>Dead</td>
</tr>
<tr>
<td>A . M</td>
<td>28</td>
<td>M</td>
<td>Chronic Glomerulonephritis</td>
<td>30</td>
<td>110</td>
<td>Living</td>
</tr>
<tr>
<td>S . M</td>
<td>15</td>
<td>M</td>
<td>Chronic Glomerulonephritis</td>
<td>5</td>
<td>13</td>
<td>Dead</td>
</tr>
<tr>
<td>R . A</td>
<td>15</td>
<td>F</td>
<td>Chronic Glomerulonephritis</td>
<td>13</td>
<td>37</td>
<td>Dead</td>
</tr>
<tr>
<td>M . M</td>
<td>9</td>
<td>F</td>
<td>Chronic Glomerulonephritis</td>
<td>0.5</td>
<td>1</td>
<td>Dead</td>
</tr>
<tr>
<td>A . H</td>
<td>30</td>
<td>M</td>
<td>Chronic Glomerulonephritis</td>
<td>0.5</td>
<td>1</td>
<td>Dead</td>
</tr>
<tr>
<td>K . M</td>
<td>42</td>
<td>M</td>
<td>Chronic Glomerulonephritis</td>
<td>0.5</td>
<td>1</td>
<td>Dead</td>
</tr>
<tr>
<td>G . E</td>
<td>42</td>
<td>M</td>
<td>Chronic Glomerulonephritis</td>
<td>10</td>
<td>31</td>
<td>Dead</td>
</tr>
<tr>
<td>M . M</td>
<td>55</td>
<td>M</td>
<td>Obstructive Uropathy</td>
<td>5</td>
<td>16</td>
<td>Dead</td>
</tr>
<tr>
<td>J . G</td>
<td>25</td>
<td>M</td>
<td>Chronic Glomerulonephritis</td>
<td>1</td>
<td>3</td>
<td>Dead</td>
</tr>
<tr>
<td>G . G</td>
<td>51</td>
<td>M</td>
<td>Obstructive Uropathy</td>
<td>15</td>
<td>44</td>
<td>Living</td>
</tr>
<tr>
<td>J . K</td>
<td>45</td>
<td>M</td>
<td>Diabetic Nephropathy</td>
<td>1</td>
<td>2</td>
<td>Dead</td>
</tr>
<tr>
<td>M . A</td>
<td>15</td>
<td>M</td>
<td>Tumour infiltration</td>
<td>3</td>
<td>8</td>
<td>Dead</td>
</tr>
<tr>
<td>J . K</td>
<td>35</td>
<td>M</td>
<td>Hypertensive nephrosclerosis</td>
<td>20</td>
<td>60</td>
<td>Living</td>
</tr>
<tr>
<td>J . A</td>
<td>35</td>
<td>M</td>
<td>Hypoplasia, Nephrosclerosis</td>
<td>10</td>
<td>31</td>
<td>Living</td>
</tr>
<tr>
<td>J . G</td>
<td>49</td>
<td>M</td>
<td>Chronic Glomerulonephritis</td>
<td>4</td>
<td>12</td>
<td>Dead</td>
</tr>
<tr>
<td>M . M</td>
<td>18</td>
<td>F</td>
<td>Hypoplasia, Nephrosclerosis</td>
<td>4</td>
<td>12</td>
<td>Dead</td>
</tr>
<tr>
<td>S . T</td>
<td>24</td>
<td>M</td>
<td>Chronic Glomerulonephritis</td>
<td>7</td>
<td>21</td>
<td>Living</td>
</tr>
<tr>
<td>H . M</td>
<td>24</td>
<td>M</td>
<td>Chronic Glomerulonephritis</td>
<td>7</td>
<td>20</td>
<td>Living</td>
</tr>
</tbody>
</table>
(b) The patients after the start of maintenance haemodialysis

Only patients dialysed for more than four weeks are considered in the analysis. The number totalled 15.

(i) Changes in weight and the concentration of certain plasma constituents

During the initial weeks of dialysis in order to control the blood-pressure, it was often necessary to reduce the patients weight by ultrafiltration during dialysis, and by restricted salt and fluid intake between dialyses.

A mean of 4.5 kg (range 0.5 to 12.5 kg.) was removed from 15 patients in their first 4 - 8 weeks of dialysis. Subsequently, the weights of the patients have been variable with some gradually increasing (4 patients) some static ( 8 patients) and some continuing to loose weight (3 patients).

In the patients dialysed for four weeks and above, the biochemical data for the last three dialysis were averaged. The mean plasma creatinine for all the patients was 250 mcmol/L range (129 - 450 mcmol/L). The mean blood urea nitrogen was 14.7 mmol/L (range 7.0 - 32.5 mmol/L).

(ii) Survival

Of the four patients on haemodialysis on 24th August 1985, one had been on dialysis for 20 weeks, two for seven weeks and one for six weeks.

Between August 1984 and August 1985 sixteen (72.7%) of the 22 patients placed on haemodialysis had died. Two
patients had renal homotransplants following 14 and 36 weeks of haemodialysis. One of the two is doing well and is being followed up. The other developed acute renal failure due to vessel thrombosis and is back on the dialysis programme awaiting a second transplant.

(iii) Deaths

There were 16 deaths in the one year period. The causes of deaths are shown in Table 12. Pulmonary oedema was the commonest cause of death accounting for 31.3% of all deaths. Pulmonary thromboembolism, uraemia, cardiac tamponade and intracranial haemorrhage each caused 12.5% of the deaths. Other causes of deaths included dialysis disequilibrium and septicaemia.

(c) Problems in haemodialysis

(i) Arteriovenous shunt problems

Upto 24th August 1985, 39 arterial cannulae have been put in place in 22 patients in 170 patient-weeks. Seventeen of these cannulae, therefore, were replacements. The mean arterial cannula survival time was therefore 4.1 weeks, otherwise expressed as an arterial cannula replacement rate of one arterial renewal per 10 patient-weeks. Similarly, 46 venous cannulae were put in place in these 22 patients. Twenty four of these venous cannulae, therefore, were replacements, and the venous cannula replacement rate was one per 7.1 patient-weeks (mean venous cannula survival time of 3.8 weeks) (Fig. 7).
Table 12:  
CAUSES OF DEATH - CHRONIC RENAL FAILURE PATIENTS ON HAEMODIALYSIS

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (Years)</th>
<th>Sex</th>
<th>Weeks of Dialysis</th>
<th>Cause of Death</th>
</tr>
</thead>
<tbody>
<tr>
<td>R . C</td>
<td>20</td>
<td>F</td>
<td>4</td>
<td>Septicaemia</td>
</tr>
<tr>
<td>B . O</td>
<td>39</td>
<td>M</td>
<td>0.5</td>
<td>Pulmonary Embolism*</td>
</tr>
<tr>
<td>M . W</td>
<td>12</td>
<td>F</td>
<td>19</td>
<td>Uraemia</td>
</tr>
<tr>
<td>L . K</td>
<td>18</td>
<td>F</td>
<td>4</td>
<td>Pulmonary oedema</td>
</tr>
<tr>
<td>S . M</td>
<td>15</td>
<td>M</td>
<td>5</td>
<td>Pulmonary oedema</td>
</tr>
<tr>
<td>R . A</td>
<td>15</td>
<td>F</td>
<td>13</td>
<td>Cardiac Tamponade*</td>
</tr>
<tr>
<td>M . M</td>
<td>9</td>
<td>F</td>
<td>0.5</td>
<td>Uraemia, septicaemia</td>
</tr>
<tr>
<td>A . H</td>
<td>30</td>
<td>M</td>
<td>0.5</td>
<td>Disequilibrium Syndrome</td>
</tr>
<tr>
<td>K . M</td>
<td>42</td>
<td>M</td>
<td>0.5</td>
<td>Pulmonary oedema</td>
</tr>
<tr>
<td>G . E</td>
<td>42</td>
<td>M</td>
<td>10</td>
<td>Cardiac Tamponade*</td>
</tr>
<tr>
<td>M . M</td>
<td>55</td>
<td>M</td>
<td>5</td>
<td>Cerebral Haemorrhage*</td>
</tr>
<tr>
<td>J . G</td>
<td>25</td>
<td>M</td>
<td>1</td>
<td>Pulmonary oedema</td>
</tr>
<tr>
<td>J . K</td>
<td>45</td>
<td>M</td>
<td>1</td>
<td>Pulmonary oedema</td>
</tr>
<tr>
<td>M . A</td>
<td>15</td>
<td>M</td>
<td>3</td>
<td>Luekaemia, Haemorrhage*</td>
</tr>
<tr>
<td>J . G</td>
<td>49</td>
<td>M</td>
<td>4</td>
<td>Cerebral Haemorrhage*</td>
</tr>
<tr>
<td>M . M</td>
<td>18</td>
<td>F</td>
<td>4</td>
<td>Pulmonary Embolism</td>
</tr>
</tbody>
</table>

* Postmortem examination done
There have been 80 clotting episodes in 22 patients in 170 patient-weeks, that is, one clotting episode per 2.1 patient-weeks.

Significant bleeding due to the presence of an arteriovenous cannula has occurred 34 times in 22 patients in 170 patient-weeks, that is one bleeding episode per 5.0 patient-weeks. One bleeding episode was due to a disconnection of the arteriovenous cannula, ten have been due to poor ligation of bleeders during institution of cannula and the rest were due to capillary oozing either due to uraemia or associated with the use of heparin infusion during haemodialysis.

A shunt infection was diagnosed when there were signs of acute inflammation at the shunt site, such as pain, tenderness, and redness (shininess) with or without pus formation. Between August 1984 and August 1985 40 shunt infections were seen; a rate of one infection per 4.3 patients weeks.

Staphylococcus aureus was responsible for 62.5% (25) of the infections; Staphylococcus albus for another 20%, 7.5% of the infections was attributed to Pseudomonas aeruginosa; 5% to Escherechia coli; and in 5% no pathogens were isolated, despite obvious signs of acute inflammation and pus formation. Photograph 8 shows one of the infected cannula sites.

Oedema of varying amount occurred in the cannulated limbs in virtually all the cases. In 5 cases the oedema was very marked and required the use of antinflammatory drugs including chymoral (Photograph 9).
Photograph 8: One of the infected cannula sites. Infection led to cannula replacement. Pus swab from this site grew *staphylococcus aureus*. 
Photograph 9: Gross oedema of the shunted limb occurring after three days.
Fig. 7: Representation of cannulations related to individual dialysis programs. Program weeks are indicated at the top of the chart (A - arterial cannulations, V - venous cannulations).
ii. **Hypertension**

All 22 patients were hypertensive (supine diastolic pressure greater than 90 mmHg), prior to starting maintenance haemodialysis (Table 13).

**Table 13:** Preprogramme and the latest predialysis blood pressures.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Preprogramme Blood Pressure</th>
<th>Latest + Predialysis Blood Pressure</th>
<th>Average + Interdialysis Weight Gain (Kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>R . C</td>
<td>180/120</td>
<td>158/103*</td>
<td>1.1</td>
</tr>
<tr>
<td>B . O</td>
<td>180/100</td>
<td>178/95*</td>
<td>2.3</td>
</tr>
<tr>
<td>M . W</td>
<td>150/100</td>
<td>118/73</td>
<td>1.6</td>
</tr>
<tr>
<td>L . K</td>
<td>240/150</td>
<td>179/111*</td>
<td>0.9</td>
</tr>
<tr>
<td>A . M</td>
<td>170/110</td>
<td>100/60</td>
<td>1.0</td>
</tr>
<tr>
<td>S . M</td>
<td>190/136</td>
<td>147/89*</td>
<td>0.8</td>
</tr>
<tr>
<td>RR . M</td>
<td>178/110</td>
<td>136/86</td>
<td>2.9</td>
</tr>
<tr>
<td>M . M</td>
<td>160/112</td>
<td>143/90</td>
<td>1.3</td>
</tr>
<tr>
<td>A . H</td>
<td>210/112</td>
<td>150/88</td>
<td>1.7</td>
</tr>
<tr>
<td>K . M</td>
<td>150/100</td>
<td>128/92</td>
<td>0.9</td>
</tr>
<tr>
<td>G . E</td>
<td>188/110</td>
<td>185/117*</td>
<td>2.5</td>
</tr>
<tr>
<td>M . M</td>
<td>200/120</td>
<td>163/95</td>
<td>1.5</td>
</tr>
<tr>
<td>J . G</td>
<td>196/140</td>
<td>143/89</td>
<td>1.9</td>
</tr>
<tr>
<td>G . G</td>
<td>140/100</td>
<td>150/90</td>
<td>1.4</td>
</tr>
<tr>
<td>J . K</td>
<td>230/160</td>
<td>200/120*</td>
<td>2.6</td>
</tr>
<tr>
<td>M . A</td>
<td>160/110</td>
<td>128/78</td>
<td>1.0</td>
</tr>
<tr>
<td>J . K</td>
<td>174/110</td>
<td>126/84</td>
<td>1.2</td>
</tr>
<tr>
<td>J . A</td>
<td>198/130</td>
<td>134/88</td>
<td>1.4</td>
</tr>
<tr>
<td>J . G</td>
<td>160/110</td>
<td>127/85</td>
<td>1.1</td>
</tr>
<tr>
<td>M . M</td>
<td>184/110</td>
<td>154/107*</td>
<td>2.2</td>
</tr>
<tr>
<td>S . T</td>
<td>176/96</td>
<td>134/82</td>
<td>0.8</td>
</tr>
<tr>
<td>H . M</td>
<td>160/100</td>
<td>140/80</td>
<td>0.9</td>
</tr>
</tbody>
</table>

* Average of three latest dialyses

* On hypotensive drugs
A degree of blood pressure control was achieved in 13 of 22 patients without the routine use of antihypertensives. The rest of the patients were either on antihypertensives or had been dialysed for a very short period. The patients whose blood pressures remained high tended to have the greater interdialytic weight gain with the tendency to developing pulmonary oedema.

(iii) Transfusion requirements

Patients were transfused when the haematocrit fell to below 21% or if it was higher but the patient was symptomatic. All patients were suffering from the anaemia of chronic uraemia. Subjectively they felt better at haematocrit readings above 24%.

The requirement for blood transfusion varied from patient to patient but averaged approximately 2 units of whole blood per month.

(iv) Pericardial effusion

Pericardial effusion was present in 5 of the 22 patients at the onset of maintenance dialysis. In two other patients the pericardial effusion was first diagnosed after 10 and 14 weeks of dialysis.

(v) Haemorrhage (haemoptysis and haematemesis)

One patient of the twenty two had recurrent haematemesis. Endoscopic examination of the upper gastrointestinal tract revealed no significant lesion. Another patient had haemoptysis on and off, but the radiological and spirometric examinations were within normal limits. Bronchoscopy was not done. Hae-
moptysis was thought to be due to the bleeding tendency of uraemia.

(vi) Febrile reactions

No significant temperature elevations were observed during dialysis, except in four occasions during transfusions, but these tended to settle in 1 - 2 hours after stopping the transfusion.

(vii) Ascites

8 of the 22 patients had ascites during haemodialysis. Three of these had had prior peritoneal dialysis with peritonitis, two had an associated pleural effusion and five had congestive cardiac failure at the time of development of ascites. In seven of the patients the ascites responded to therapy with diuretics, antibiotics where indicated and to ultrafiltration during dialysis. In one patient the ascites developed in the absence of any predisposing cause and was not responsive to any of the above forms of therapy and repeated tapping. The latter patient had progressively increasing ascites and cachexia and was considered to have refractory ascites of haemodialysis.

Tables 14 and 15 show the clinical features and pertinent laboratory data on the eight patients. Figure 8 shows the temporal relationship between haemodialysis and ascites.

Photograph 10 shows the patient considered to have refractory ascites of haemodialysis.
# Clinical Features of Eight Patients with Ascites During Haemodialysis

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age in Years (SEX)</th>
<th>Presumed Diagnosis</th>
<th>Peritoneal Dialysis</th>
<th>Duration, weeks of Ascites on HD</th>
<th>Severity of Ascites</th>
<th>Peri-Pheral Oedema</th>
<th>Pleural Effusion</th>
<th>Pericarditis</th>
<th>Congestive Heart Failure</th>
<th>Hyper- Tension</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>R . C</td>
<td>20 (F)</td>
<td>Chronic glomerulonephritis</td>
<td>YES</td>
<td>10 - 6</td>
<td>Moderate</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>NO</td>
<td>Dead</td>
</tr>
<tr>
<td>L . K</td>
<td>18 (F)</td>
<td>Hypertensive Nephrosclerosis</td>
<td>NO</td>
<td>2 + 2</td>
<td>Mild</td>
<td>NO</td>
<td>NO</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
<td>Dead</td>
</tr>
<tr>
<td>A . M</td>
<td>28 (M)</td>
<td>Chronic glomerulonephritis</td>
<td>NO</td>
<td>3 + 14</td>
<td>Mild</td>
<td>NO</td>
<td>NO</td>
<td>NO</td>
<td>NO</td>
<td>NO</td>
<td>Alive</td>
</tr>
<tr>
<td>R . A</td>
<td>15 (F)</td>
<td>Chronic glomerulonephritis</td>
<td>YES</td>
<td>36 - 22</td>
<td>Moderate</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>Dead</td>
</tr>
<tr>
<td>E . G</td>
<td>42 (M)</td>
<td>Chronic glomerulonephritis</td>
<td>YES</td>
<td>16 - 6</td>
<td>Moderate</td>
<td>NO</td>
<td>NO</td>
<td>YES</td>
<td>NO</td>
<td>YES</td>
<td>Dead</td>
</tr>
<tr>
<td>M . M</td>
<td>18 (F)</td>
<td>Renal Hypoplasia with Nephrosclerosis</td>
<td>NO</td>
<td>6 - 2</td>
<td>Mild</td>
<td>YES</td>
<td>NO</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
<td>Dead</td>
</tr>
<tr>
<td>J . K</td>
<td>35 (M)</td>
<td>Hypertensive Nephrosclerosis</td>
<td>NO</td>
<td>8 + 12</td>
<td>Mild</td>
<td>YES</td>
<td>NO</td>
<td>YES</td>
<td>YES</td>
<td>YES</td>
<td>Alive</td>
</tr>
</tbody>
</table>

1. Duration of Haemodialysis before appearance of Ascites.
<table>
<thead>
<tr>
<th>Patient</th>
<th>Age in Years (SEX)</th>
<th>Serum Protein</th>
<th>Culture</th>
<th>Specific gravity</th>
<th>Total Protein</th>
<th>Albumin globin ratio</th>
<th>White blood cells</th>
<th>%Lymphocytes</th>
<th>Proteinuria</th>
<th>Prothrombin index</th>
<th>ALT</th>
</tr>
</thead>
<tbody>
<tr>
<td>R . C</td>
<td>20 (F)</td>
<td>67 g/L 32 g/L</td>
<td>Pseudomonas aeruginosa</td>
<td>1.020</td>
<td>32 g/L</td>
<td>1.38</td>
<td>750/mm³</td>
<td>34%</td>
<td>Trace</td>
<td>78%</td>
<td>26K.U</td>
</tr>
<tr>
<td>L . K</td>
<td>18 (F)</td>
<td>62 g/L 34 g/L</td>
<td>Negative</td>
<td>1.014</td>
<td>20 g/L</td>
<td>-</td>
<td>10/3 mm</td>
<td>100%</td>
<td>Nil</td>
<td>100%</td>
<td>15K.U</td>
</tr>
<tr>
<td>A . M</td>
<td>28 (M)</td>
<td>66 g/L 33 g/L</td>
<td>Negative</td>
<td>-</td>
<td>26 g/L</td>
<td>-</td>
<td>5/3 mm</td>
<td>100%</td>
<td>Nil</td>
<td>70%</td>
<td>38K.U</td>
</tr>
<tr>
<td>R . A</td>
<td>15 (F)</td>
<td>60 g/L 31 g/L</td>
<td>Staphylococcus Aureus</td>
<td>1.023</td>
<td>33 g/L</td>
<td>1.13</td>
<td>1050/3 mm</td>
<td>40%</td>
<td>Trace</td>
<td>84%</td>
<td>52K.U</td>
</tr>
<tr>
<td>E . G</td>
<td>42 (M)</td>
<td>71 g/L 35 g/L</td>
<td>Negative</td>
<td>1.019</td>
<td>28 g/L</td>
<td>1.00</td>
<td>1180/3 mm</td>
<td>30%</td>
<td>Nil</td>
<td>100%</td>
<td>45K.U</td>
</tr>
<tr>
<td>G . G</td>
<td>51 (M)</td>
<td>75 g/L 33 g/L</td>
<td>Negative</td>
<td>1.021</td>
<td>35 g/L</td>
<td>2.60</td>
<td>500/3 mm</td>
<td>80%</td>
<td>Trace</td>
<td>88%</td>
<td>43K.U</td>
</tr>
<tr>
<td>J . K</td>
<td>35 (M)</td>
<td>68 g/L 34 g/L</td>
<td>Negative</td>
<td>1.012</td>
<td>20 g/L</td>
<td>-</td>
<td>20/3 mm</td>
<td>100%</td>
<td>Nil</td>
<td>80%</td>
<td>48K.U</td>
</tr>
<tr>
<td>M . M</td>
<td>18 (F)</td>
<td>63 g/L 36 g/L</td>
<td>Negative</td>
<td>1.014</td>
<td>26 g/L</td>
<td>-</td>
<td>10/3 mm</td>
<td>100%</td>
<td>Nil</td>
<td>67%</td>
<td>50K.U</td>
</tr>
</tbody>
</table>

ALT - Alanine aminotransferase
Photograph 10: G.G., A patient thought to have developed Idiopathic ascites of haemodialysis. Note the gross ascites and marked wasting.
* - Prior peritoneal dialysis
(viii) Hepatitis

Of the 22 patients with chronic renal failure so far dialysed, one has had serological (Hepatest) evidence of hepatitis B virus infection. None has had any clinical or biochemical evidence of hepatitis.

After working in the dialysis unit for about nine months one staff member has developed clinically, biochemically and serologically proven hepatitis B virus infection.

(ix) Hearing loss

Audiograms were obtained in 4 of the patients. All the four were abnormal, showing varying degrees of bone conduction abnormalities. In one patient who clinically had a hearing defect, the gross abnormality was temporarily related to the administration of large doses of lasix at the initiation of dialysis.

(x) Pulmonary Oedema between dialyses

Ten of the 22 patients developed sixteen episodes of pulmonary oedema in interdialytic period. In 5 of them this was fatal. The pulmonary oedema was diagnosed clinically and with the help of radiology in some cases. The cause of the pulmonary oedema was considered to be due to fluid overload in patients who were anaemic, hypertensive and had impaired cardiac function.
(xi) Disequilibrium Syndrome

This was seen in 3 of the 22 patients. In all it occurred during the first dialysis. It was characterised by headache, nausea, vomiting, hypertension, restlessness, twitches, convulsions, confusion and coma. One of the patients died. The other two were salvaged by infusion of mannitol. The three patients who developed disequilibrium syndrome had high predialysis blood urea nitrogens (87.5, 77 and 166 mmol/L) and correspondingly high serum creatinine level (1000, 874, 1800 mcmol/L). These dropped to (45.6, 44.0 and 56.0) and (820, 546 and 1050) respectively, after dialysis.

(xii) Hypotension, Muscle cramps, Nausea, vomiting, headache

In a total of 503 dialyses carried out in patients with acute and chronic renal failure, hypotension was observed in 26%, muscle cramps in 20%, nausea and vomiting in 15%, headache in 18%.

(xiii) The first-use Syndrome

This occurs as a feeling of ill-being at the start of dialysis with a new dialyser. The syndrome is characterised by dyspnoea, chest constriction, nausea, vomiting and hypotension, sometimes culminating in cardiopulmonary collapse. This has occurred in one patient of the 42 who have been started on haemodialysis.
V. DISCUSSION

That haemodialysis is of value in acute renal failure, chronic renal failure, acute intoxications and in states of overhydration is uncontestable (24). Less well defined indications of haemodialysis have included myasthenia gravis (44), Schizophrenia (44) and Psoriasis (45).

At the Kenyatta National Hospital haemodialysis has exclusively been carried out in patients with various renal failure syndromes and in states of overhydration related to the presence of renal diseases. No patient with acute intoxication has so far been started on haemodialysis. This has been in part due to the limited availability of dialysis and staff. On the other hand most intoxications have occurred in the paediatric age groups and peritoneal dialysis and/or conservative management have been given preference because of the problems encountered with angioaccess for haemodialysis in this age group.

In the period between July 1973 and June 1982, haemodialysis at Kenyatta National Hospital was specifically meant for patients with acute renal failure in whom recovery was anticipated (90). The other patients dialysed either had acute on stable chronic renal failure and had haemodialysis to tide them over the acute phase or had unidentified renal disease and were dialysed to allow time for confirmation of diagnosis. Recently, with the establishment of a dialysis centre at the hospital, there has been a deliberate effort to start patients with confirmed chronic renal failure on maintenance haemodialysis, all with a view to giving them renal transplantation at some time or another. The choice of the patients has been made using the
guidelines outlined in appendix I.

For the past two and a half decades, the emphasis in most centres has been on prophylactic dialysis for acute renal failure rather than waiting until pushed by a catastrophic biochemical or clinical occurrence (14, 91 - 93). This principle has been followed at Kenyatta National Hospital recently, where of 20 patients with acute renal failure in a one year period (August 1984 to August 1985), none was moribund at the onset of haemodialysis and had biochemical parameters as follows: potassium 6.2 ± 1.3 mmol/L (mean ± 2sD), blood urea nitrogen 32.5 ± 5.4 mmol/L (mean ± 2sD) and serum creatinine 345 ± 100 micmol/L (mean ± 2sD). In the earlier period (July 1973 to June 1982), 48% of the 31 patients with acute renal failure started on haemodialysis were moribund and the biochemical parameters were 5.6 ± 2.8 mmol/L (mean ± 2sD) for potassium, 55.5 ± 10.4 mmol/L (mean ± 2sD) for blood urea nitrogen and 417 ± 216 micmol/L for serum creatinine.

The mortality in patients with acute renal failure on haemodialysis was 30% for the patients started on haemodialysis between August 1984 and August 1985 as compared to 61.3% in patients with acute renal failure dialysed between July 1973 and June 1982. The former figure is closer to the ones reported in other series (14, 92, 94 and 95).

The mortality in acute renal failure is influenced by various factors apart from timing and frequency of dialysis. Thus, Teschan and associates (14) in 1960 found that when renal
failure is due to obstetrical accidents, the mortality was 7% with prophylactic dialysis and 15% without it. The corresponding figures for acute renal failure of medical aetiologies was 29% and 40%. The mortality in postsurgical and post traumatic renal failure ranges from 47% (14) to 67% (95). These figures are higher in the presence of associated sepsis (44). Age has been a major factor associated with increased mortality in some series (96). In the retrospective study, 46.3% of the patients who died had gynaecological problems associated with sepsis and disseminated intravascular coagulation, 6.4% obstetrical haemorrhage and 10.3% surgery with haemorrhage. All the patients were below 50 years of age. The mean blood urea nitrogen for the patients who died was $64.3 \pm 12.2 \text{ mmol/L}$. Thus the major causes of mortality seemed to be the degree of uraemia and the nature of the primary illness causing the uraemia. In the 6 patients with acute renal failure who died in the prospective study period, all developed acute renal failure post-surgery, except for one who had cholera, but died of pulmonary oedema due to overzealous fluid replacement without close monitoring.

The first deliberate attempt to restore useful life through repeated dialysis of a patient with obviously terminal, irreversible renal disease was reported by Scribner and his associates in 1960 (17). Before then haemodialysis was deemed of limited value in the treatment of chronic renal failure (15, 16). Two and a half decades after the recognition of the usefulness of haemodialysis in the management of chronic renal failure, little information exists as to its application in the
African continent. There is evidence, however, that it has been used in South Africa extensively (97, 98) and to some extent in Egypt (87). At the Kenyatta National Hospital, deliberate use of haemodialysis in patients with chronic renal failure has been going on for only one year (August 1984 to August 1985). Before then haemodialysis was restricted to patients with reversible renal disease (89, 90).

The criteria for selection of patients for the chronic haemodialysis and transplant programme are outlined in Appendix I. There is no accurate data as to the mortality rate of chronic renal failure in Kenya at the moment, but so long as treatment capability remains low, the onerous task of patients selection must go on. There is as yet no universally acceptable set of criteria by which such decisions can be made, nor is one likely to be developed which is consonant with all values of civilized man (99, 100). Human worth is not measurable except by arbitrary standards, with or without the aid of "Selection committees" and prediction as to total response to any patient prior to clinical trial remain precarious.

Age alone is no longer a leading consideration in selecting patients for most haemodialysis programmes (101, 102). The presence of other diseases which might limit the clinical benefits of dialysis constitute a contraindication. In some instances, diabetes (103), Goodpastures syndrome (104), and lupus erythematosus (115) have not precluded the success of chronic dialysis. Estimates of the patients' intelligence, discipline, motivation and family setting, tend to enter into the decision-making process (99, 100, 107). In truth, however, it must be
recognised that a major determinant of patient selection is simply whether or not a chronic dialysis facility exists in the area, and whether or not it can accept another patient. It can be argued that a "first come first served" basis may be the only ethically acceptable one. Examination of our total experience in the area of shunt survival reveals a mean survival of 4.1 weeks for arterial cannulae and 3.8 weeks for venous cannulae. This is considerably less than the 12.4 and 13.9 months survival reported by Pendras and associates (108) and 4.8 and 4.5 months survival reported by Schupak et al (109).

The commonest shunt complication in this study has been clotting, occurring at a rate of one episode per 2.1 patient-weeks. Infections occurred at a rate of one per 4.3 patient-weeks and significant bleeding at a rate of one episode per 5.0 patient-weeks. The commonest infecting organism in this study was *Staphylococcus aureus*, accounting for 62.5% of the infections. This is similar to what is reported in other series (110, 111, 112). The short survival time for our cannulae can be explained on the basis of the complications above, which in turn can be explained on the basis of (a) hesitancy to use specific antibiotics for specific infections, (b) insertion of cannulae by varying groups of doctors, most with little experience in cannula surgery, and (c) lack of appropriate cannulae care once inserted because of shortage of staff experienced in cannula care.

In this study all the patients with chronic renal failure started on haemodialysis were hypertensive (supine diastolic pressure greater than 90 mm Hg). The mean blood pressures of all
the patients before the start of haemodialysis was $181 \pm 12$
mm Hg systolic by $116 \pm 6$ mm Hg diastolic. Following a minimum of four weeks dialysis the corresponding figures were $146 \pm 5.5$ mm Hg and $91 \pm 6.2$ mm Hg. In the patients in this study blood pressures control was achieved by ultrafiltration alone in 59% of the patients. The other patients required to be on hypotensive drugs for control of blood pressure, but none seemed resistant to most antihypertensives, except one.

There are two main factors in the aetiology of hypertension in patients with chronic renal failure: Volume and salt overload and the renin-angiotensin system (113). In 80-90% of patients control of hypertension is normally achieved by dietary restriction of salt and water and ultrafiltration during dialysis. In the remaining 10-20%, antihypertensives and occasionally bilateral nephrectomy is required for control of blood pressure (113). This latter group is usually considered to have hypertension due to elevated plasma renin levels. In this study it has not been possible to estimate the plasma renin levels in the patients. Additionally, dietary restriction in the patients has been very difficult. This could account for the low percentage of patients whose hypertension have been controlled by ultrafiltration. Bilateral nephrectomy is currently being considered for one patient (J, K.) who has been on dialysis for twenty weeks and has been treated with maximum dosages of antihypertensives without achieving control of blood pressure.

In patients in this study, hypotension has occurred in 26% of the 503 dialyses, while muscle cramps have occurred in
20%. Reports from other centres give prevalence of hypotension as 22 - 44% and that of muscle cramps as 13 - 54% (58, 114 - 117).

Hypotension is a frequent occurrence in chronic haemodialysis patients during the dialysis procedure. The subject has been reviewed in detail by Rubin and Gutman (118), who summarised the well known cardiac factors (coronary-artery disease, cardiomyopathy, pericardial involvement, arrhythmias), haemodynamic factors (anaemia, arteriovenous fistulae, extracellular fluid volume changes, altered peripheral resistance), pulmonary factors (pulmonary oedema, calcification, infection), and dialysis-related factors (ultrafiltration, blood loss, endotoxaemia, bacteraemia, haemolysis, hypoxaemia, acetate infusion, osmolality changes). In this study, episodes of hypotension occurred during attempts at ultrafiltration in 70%. In the other cases no obvious predisposing factor was detectable, except for anaemia which was present in all the patients and acetate which was present in the dialysate used in all the patients.

It is generally accepted that muscle cramps are unavoidable accompaniments of dialysis, especially when a lot of fluid is removed, and that palliative treatment is all that is required for these complication (119). In this study the sodium concentration in the dialysate was 138.0 mmol/l and the glucose was 3.0 g/l. The high strength of the dialysate in this study could explain the relative infrequency of muscle cramps.

In this study transfusion requirement averaged 2 units of whole blood per month. Patients were not transfused unless they were symptomatic or the haematocrit fell to below 21%. All the
patients had anaemia attributable to their chronic renal failure. Other possible causes of anaemia included blood loss from the shunt site, withdrawal of blood for analysis at each dialysis, blood loss into the dialyser at the end of dialysis, inadequate nutritional intake due to inadequate dialysis and possible infections. Thomson and associates (120) report a requirement of 2.5 units of packed red blood cells per month in adequately dialysed patients. In the recent past, deliberate transfusion, based on immunetolerance has been advocated to promote graft survival in patients due to have homotransplants (121).

23% of the patients in this study had pericarditis with effusion before the onset of haemodialysis. All of these resolved on dialysis. Two patients however developed pericarditis with effusion 10 and 14 weeks after the onset of haemodialysis. These were attributed to inadequate dialysis with ongoing uraemia. Pericarditis has become recognised as an important cause of morbidity in patients on a chronic, intermittent haemodialysis programme. Barber and colleagues (122) found evidence of pericarditis in four out of thirteen post-mortem examinations performed after prolonged haemodialysis. Comty and associates (123) reviewing pericarditis in chronic uraemia found an incidence of 16% in all patients accepted for haemodialysis. Mitchell (124) reported pericarditis in 18% of patients accepted for haemodialysis.

It is possible that chronic dialysis modifies the natural history of uraemic pericarditis to produce a distinct form of illness. It is felt, though, that is a separate disease. The aetiology remains obscure and while infective illnesses pre-
dispose to pericarditis, there is little evidence that the peri-
carditis is infective (24). Pabico and associates have suggested
that cytomegalovirus may act as a causative agent (125).

Ascites resistant to treatment has become an increasingly
recognised problem in many dialysis centres. In the majority of
patients described, no specific cause of ascites has been
described (81, 82). Previous peritoneal dialysis has been con-
sidered to play an aetiological role in such patients (82).
Investigators have treated these patients in several ways: with
continuous drainage, frequent paracentesis, exploratory
laparotomy and total ascites drainage, bilateral nephrectomy, or
kidney transplant all with different results (126 - 131).
Recently, the use of non-absorbable triamcinolone, oral indome-
thacin and intraperitoneal radioactive chromium have been tried
with some positive results (132).

In this study eight of the 22 patients had ascites during
haemodialysis. In five of these the ascites was considered to
be due to fluid overload and congestive cardiac failure. In
another two, previous peritoneal dialysis and peritonitis were
considered responsible. In one patient (G. G) exudative ascites
developed without any obvious precipitating cause. The ascites
progressively increased in size and was associated with marked
cachexia. It showed no response to frequent attempts of ultra-
filtration. This patient was considered to have idiopathic
ascites of haemodialysis. Becerra and Ontiverous (132) postulate
that ascites of uraemic patients on haemodialysis is a part of
what they call "Uraemic polyserositis" and that it is caused by
inflammation. In some published reports of patients with ascites
undergoing long-term haemodialysis, hypoproteinaemia was the rule (128 - 131). The possibility of altered peritoneal permeability because of repeated peritoneal dialysis has been advanced as a cause (130, 131). Overhydration has been the constant feature in some reported cases (127 - 129).

Dialysis disequilibrium syndrome was first described by Kennedy in 1962 (133). It was him who proposed the pathophysiological explanation of a "reverse urea effect" the mechanism of which is the rapid build-up of an osmotic gradient across each side of the blood-brain barrier. Confirmation of this hypothesis was obtained by the work of Dossetor and Zborowski (134) who prevented or reduced the clinical disorder by additions of urea to the dialysis bath. However, more recent studies have shown in fact that this simple mechanism is not sufficient to explain the disequilibrium syndrome. Arieff and associates (52) have demonstrated in the dog that a rapid dialysis creates an osmotic gradient between;

(1) Plasma and cerebrospinal fluid, and
(2) Cerebrospinal fluid and brain cells, the water content of which increases. However, they failed to identify the osmotically active substance(s) which they simply defined as "idiogenic osmoles".

Evidence has also been presented for mechanisms other than merely "osmotic", for example, rapid swings of acid base balance (51), of blood glucose (135), of serum calcium (51), of serum sodium and of the hydration state (51). Another interesting hypothesis deals with the correction of acidosis and hyperphosphataemia which is able to shift the HbO₂ dissociation curve
to the left whereby tissue hypoxia due to renal anaemia might be aggrevated (136),

The usual clinical descriptions of this syndrome are relatively simple (133) and consist of headache, nausea and vomiting, drowsiness or agitation, muscular cramps and twitching. More severe disorders such as disorientation and mental confusion with occasional asterixis can occur and in some cases acute psychosis, seizures, stupor and coma are also seen.

The clinical signs and symptoms occur mainly during the first haemodialysis (137). They disappear in less than 36 hours. The rate of change of serum sodium, urea or other substance is probably more important than is the quantity of any substance removed (138).

In this study three of the twenty two patients developed disequilibrium syndrome during or immediately after the first dialysis. One of the patients died while the other two were salvaged by mannitol infusion. The patients who developed disequilibrium syndrome had very high predialysis blood urea nitrogen and were extremely acidotic. Attempts at preventing dialysis disequilibrium have included prior peritoneal dialysis or haemodialysis of short duration and low blood flow rates to facilitate a gradual fall in the serum concentration of the osmotically active substance.

Acute pulmonary oedema is a frequent emergency in dialysed patients (139). It may be a reflection of pericarditis, masked valvular heart lesion and cardiomyopathy associated with uraemia (123, 139, 140). However, the commonest causes of pulmonary
oedema between dialysis are inadequate dialysis and poor fluid and salt control (141) in patients who are already anaemic, have heart muscle disease due to uraemia and/or hypertension and are bound to be hypoproteinaemic due to their renal disease. Robson and associates consider the use of high dialysate sodium concentration as a possible cause of pulmonary oedema in patients on haemodialysis (142). An interesting pulmonary oedema associated with blood membrane complement mediated pulmonary leucostasis evoking mild pulmonary oedema has been described (143).

In this study ten of the twenty two patients on maintenance dialysis developed sixteen episodes of pulmonary oedema. 31.3% of these episodes were fatal. The common reasons for developing pulmonary oedema were severe hypertension (diastolic blood pressure greater than 120 mm Hg), anaemia (Haemoglobin less than 8 g/dl), inadequate dialysis with poor removal of fluid, clotted shunts with inability to get access sites and in some situations, inability to get dialysis fluid in time.

The syndrome of "first-use" is characterised by dyspnoea, chest constriction or angina, nausea, vomiting and hypotension, sometimes culminating in cardiopulmonary collapse (144). Hakim and associates (145) described this syndrome in 3% to 5% of their dialysis population and attributed its occurrence to the in vivo complement activation by a new cuprophan membrane. This has been confirmed by several investigators (146 - 148), who presented convincing evidence by quantitative determination of the generation of complement fraction C3a.
In the current study, one patient of the 22, developed the syndrome at each dialysis, stabilising only after some period of dialysis, usually 30 - 60 minutes. At our centre all dialysers are currently used only once and thereafter discarded.

In the current study 72.7% of the twenty two patients with chronic renal failure started on maintenance haemodialysis have died. This is in sharp contrast to the annual mortality of 7 - 10% reported in other series (84, 85). The commonest causes of death in this study were congestive cardiac failure and pulmonary oedema due to inadequate dialysis and fluid overload (31.3%), pulmonary embolism (12.5%), uraemia (12.5%), cardiac tamponade (12.5%) and intracranial haemorrhage (12.5%). Other causes of death were dialysis disequilibrium. This compares with causes of death in European dialysis centres in the late sixties where prominent causes of death were congestive cardiac failure, electrolyte imbalances and infections (149).
REFERENCES

1. OTIENO, L. S.; A history of haemodialysis. 


   J. Pharmacol. and Exper. Therap. 5: 275, 1914.

5. KOLFF, W. J. and BERK, H. T. J.: Artificial kidney, dialyser with great area. 


9. KOLFF, W. J.: First clinical experience with the artificial kidney. 


12. BLUEMILE, L. W. JR., WEBSTER, G. D. JR. and ELKINTON, J. R.: Acute tubular necrosis; analysis of 100 cases with respect to mortality, complications and treatment with and without dialysis. 

13. ALWALL, N., ERLANSON, P., TORNBERG, A., MOELL, H. and FAJERS, C. M.: Two cases of gross renal cortical necrosis in pregnancy with severe oliguria and anuria for 116 and 79 days, respectively; clinical course, roentgenologic studies of the kidneys (size, outline and calcification), and post-mortem findings. 


29. COMTY, C. M., LUEHMANN, D., WATHEN, R. and SHAPIRO, F.;水治疗法

水治疗法


30. KOPP, K. F., GUTCH, C. F. and KOLFF, W. J.; 单针

单针

Tr. Am. Soc. Artif. Intern. Organs. 18:

75, 1972.

31. QUINTON, W., DILLARD, D. and SCRIBNER, B. H.; 搪塞血

搪塞血

Tr. Am. Soc. Artif. Intern. Organs., 6:


32. KURUVILA, K. and BEVEN, E. G.; 阿里乔斯静脉瘘和

阿里乔斯静脉瘘和


33. CHAVEZ, C. M. and BOWER, J. D.; 股-股静脉瘘作为

股-股静脉瘘作为


34. SCHREINER, G. E., MAHER, J. F., FREEMAN, R. B. and

O'CONNELL, J. M. B.; 泌尿科的血透

泌尿科的血透


35. THOMAS, G. L.; 大血管的阿利乔斯静脉瘘

大血管的阿利乔斯静脉瘘

Am. J. Surg. 120: 244, 1970.


41. ERBEN, J., KVASNICKA, J., BASTECKY, J. and
VORTEL, V.: Experience with routine use of subclavian
vein cannulation in haemodialysis.
Proceed Euro Dial Transplant Assoc. 6:
59, 1969.

42. SECHAS, M., BILLIS, A., DAIKOS, G. and SKALKEAS, G.:
Chronic intermittent haemodialysis by
repeated paracentesis of the femoral vessels.

43. WOLFF, A. V., REMP, D. G., KILEY, J. E.,
and CURRIE, G. D.: Artificial kidney function: kinetics
of haemodialysis.

44. SHINABERGER, J. H: Indications for haemodialysis, from clinical
aspects of uraemia and dialysis - by
MASSRY, G. S. and SELLERS, L. A. (Ed).,
Charles. C. Thomas, Publisher, Springfield.

45. BUSELMEIER, J. T., KJELLSTRAND, C. M., DAHL, M. V.,
CANTIERI, J. S., NELSON, R. S., BURGDORF, W. C.,
BENTLEY, C. R., NAJARIAN, J. S., GOLTZ, R. W.: Treatment
of psoriasis with dialysis.
Proceed Euro Dial Transplant Assoc. 15:
46. MERRILL, J. P. GIORDANO, C., HEETDERKS, D. R.:
The role of the kidney in human hypertension.
(1) Failure of hypertension to develop in renoprival subject.

47. LAZARUS, J. M., LOWRIE, E. G., HAMPERS, C. L., MERRILL, J. P.: Cardiovascular disease in uraemic patients on haemodialysis.
Kidney Int. 2 (Suppl.): 167, 1975.


51. WAKIM, K. G.: The pathophysiology of the dialysis disequilibrium syndrome.


56. PORT, F. K., EASTRLING, E.: Evaluation of acetate tolerance during highly efficient haemodialysis.


64. KJELLSTRAND, C. M., EATON, J. W., YAWATA, Y.,
SWOFFORD, H., KOLPIN, C. F., BUSELMEIER, J. J.,
VONHARTITZSCH, B., JACOBS, H. S.: Haemolysis in
dialysis patients caused by chloramines.

65. PARKINSON, I. S., BECKETT, A., WARD, M. K., FEEST, T. G.,
HOENICH, N., STRONG, A., KERR, D. N. S.: Aluminium:
removal from water supplies.

66. LAWRENCE, W. K., AUTIAN, J., MISRA, P. K.: Cardioactive
substances leached from a commercial
haemodialysis set.

67. BOMMER, J., EBERHARD, R., KONRAD, A.: Nectrotizing
dermatitis resulting from haemodialysis
with polyvinyl chloride tubing.

68. NEERGAARD, J., NIELSEN, B., FAURBY, V., CHRISTENSEN, D. H.
and NIELSON, E. F.: Plasticizers in Polyvinyl chloride and
the occurrence of hepatitis in a haemo-
dialysis unit.

69. CRADDOCK, P. R., FEHR, J., BRIGHAM, K. L.,
KRONENBERS, R. S., JACOBS, H. S.: Complement and leukocyte
mediated pulmonary dysfunction in haemo-
dialysis.


Kidney Int. 16: 600, 1979.
76. BALL, J., JOHNSON, J. W., HAMPERS, C. L., MERRILL, J. P.:
The many facets of secondary hyperparathyroidism.

77. TYLER, H. R.;
Neurologic disorders in renal failure.

78. ALFREY, A. C., MISHELL, J. M., BURKS, J.,
CONTIGUGLIA, S. R., RUDOLPH, H., LEWIN, E., HOLMES, J. H.:
Syndrome of dyspraxia and multifocal seizures associated with chronic haemodialysis.

Possible aluminium intoxication.

80. DUNEA, G., MUHURKAR, D. G., MAMDANI, B., SMITH, E. C.:
Role of aluminium in dialysis dementia.

81. LEORNARD, A., SHAPIRO, F. L: Subdural haematoma in regularly haemodialysed patients.

82. GABRIEL, S. A., MARK, W. I., HAMPTON, W. R., MAHER, J. F.:
The clinical spectrum of Ascites associated with maintenance dialysis.
83. GILCHREST, B. A., ROWE, J. W., BROWN, R. S., STEINMAN, T.
    STEINMAN, T. I., ARNDT, K. A.: Relief of uraemic pruritis
    with ultraviolet phototherapy.

84. SIDDIQUI, Y. J, FITZ, E. A., LAWTON, L. R.,
    KIRKENDALL, M. W.: Causes of death in patients receiving
    long-term haemodialysis.

85. BURTON, T. B., KRUEGER, K. K., Bryan, A. F. JR.:
    National Registry of long-term dialysis
    patients.

86. ABU-ASHA, H., IBRAHIM, A., SALIH, M. A., BELEIL, O. M.:
    Experience with renal allotransplantation.
    Case report.

87. HASSABALLA, A. M., EL-AYADI, A., SHAHEEN, M. H.,
    BARSOUM, R. S. and EL-DADRY, A.: Sodium and Urea
    diffusion patterns in fresh versus re-use Kolff coil dialysers.

    Dialysis experience in Sudan.
89. OTIENO, L. S., MWACHANDI, L. N., AMOLO, M. O.,
KIOKO, E. M., ABDULLAH, M. S., ONGERI, S. K.,
KINUTHIA, M. D. W., MWONGERA, F. K.: Disequilibrium
syndrome in haemodialysis at Kenyatta
National Hospital Intensive Care Unit.

90. AMOLO, M. O., ABDULLAH, M. S., OTIENO, L. S.,
and MWACHANDI, L. N.: Haemodialysis at the Kenyatta
National Hospital Intensive Care Unit,

91. SCRIBNER, B. H., MAGID, G. J.,
and BURNELL, J. M.: Prophylactic haemodialysis in the
management of acute renal failure.

92. EASTERLING, R. E., and FORLAND, M.: A five year ex-
pperience with prophylactic dialysis in
acute renal failure.

93. HOLMES, J. H.: Acute tubular necrosis and its
management.

94. KIRKLAND, K., EDWARDS, K. D. G.,
and WHYTE, H. M.: Oliguric renal failure: A report of
400 cases including classification,
survival and response to dialysis.
95. STOTT, R. B., OGG, C. S., CAMERON, J. S.,
and BEWICK, M.: Why the persistently high mortality in acute renal failure?

96. BENSON, L. E., ROBERTS, L. W.,
and SANFELIPPO, M. L.: Evaluation of early and frequent haemodialysis for acute renal failure in older age groups.


99. STUMPF, S. E.: Some moral dimensions of medicine.

100. ELKINTON, J. R.: Moral problems in the use of borrowed organs, artificial and transplanted.

Kidney Int. 7: 1, 1974.


110. EYKYN, S., PHILIPS, I., and EVANS, J.: Vancomycin for staphylococcal shunt site infections in patients on regular haemodialysis. 


112. SHERRARD, D. J.: Infections in haemodialysis patients. 

113. PEGGY, G. R. N.: Hypertension and hypotension in dialysis patients. 


119. STEWART, W. K., LAURA, W. F. and MANUEL, M. A.: 
Muscle cramps during maintenance haemodialysis. 


121. BRYNGER, H., FRISH, B., AHLMENS, J., ATTMAN, P. O.; BLOHME, I., SANDBERG, L. and GELIN, L. E.: Graft survival and Blood transfusion. 


140. LAZARUS, J. M., LOWRIE, E. G., HAMPERS, C. and MERRILL, J. P.: Cardiovascular disease in uraemic patients on haemodialysis.


147. CHENOWETH, D. E., CHEUNG, A. K. and HENDERSON, L. W.: 
Anaphylatoxin formation during 
haemodialysis. Effects of different 
dialyser membranes. 
**Kidney Int. 24: 764, 1983.**

148. CHENOWETH, D. E., CHEUNG, A. K. and WARD, D. M.: 
Anaphylatoxin formation during haemo- 
dialysis: Comparison of new and 
reused dialysers. 
**Kidney Int. 24: 770, 1983.**

149. DUKKER, W., JUNGERIUS, N. A. and ALBERTS, C.: Report 
on regular dialysis treatment in 
Europe. 
**Proceed Euro. Dial and Transplant 
Assoc. 3: 3, 1968.**

150. LEVY, B. N.: Coping with maintenance haemodialysis - 
Psychological considerations in the 
care of patients: In: clinical 
aspects of uraemia and Dialysis, p.53. 
Charles C. Thomas. Publisher. 
VII. APPENDIX I

KENYATTA NATIONAL HOSPITAL RENAL UNIT

POLICY FOR ACCEPTABILITY OF DIALYSIS TREATMENT AND TRANSPLANTATION

Acute Renal Failure (ARF)

1. All patients with reversible acute renal failure without advanced malignancies.

2. Patients will be individually assessed by the Renal Team eventually, but under emergency situation the nephrologist on call will decide on the immediate treatment.

3. The guidelines for immediate treatment of acute renal failure should include too much fluid accumulation, elevation of potassium, urea, creatinine and presence of acidosis.

Chronic Renal Failure (CRF)

General criteria for acceptance of dialysis:

1. The patient must be transplantable.

2. Patients must have no serious medical problems (advanced malignancies, elderly or complicated diabetics, nor beyond 55 years and complicated collagen diseases).

3. Must have no serious mental or physical handicap.

4. Patients who are socially, educationally and economically useful to the society.

5. The patient must be well motivated.

6. The family must not only be well motivated but also concerned and actively involved.
7. The home and social circumstances must be favourable.
8. The final decision on the acceptability or non-acceptability of the individual patient must remain with the renal team.

Peritoneal Dialysis for CRF

All patients who meet the general criteria set above.

Haemodialysis

1. All the criteria for ARF and CRF must be met.
2. Patients must be HBs Ag negative but those who are positive will be put on an identified machine in isolation room.

Acceptability for Transplantation

1. Must meet all the general criteria.
2. Should not be beyond 55 years.
3. Should have live related donor.
4. Should ideally be HBs Ag negative.
5. Should accept alternative treatment should transplantation fail.

CAPD (Continuous Ambulatory Peritoneal Dialysis)

1. General criteria should be met (for CRF).
2. This treatment can be offered to CRF patients awaiting transplantation or those in whom transplantation has failed, or those who have no vascular access or those who cannot tolerate haemodialysis.
IPD (Intermittent Peritoneal Dialysis)

1. All general criteria should be met (for CRF).
2. Suitable for patients who are over 55 years old or those who for other reasons cannot be offered other forms of dialysis or transplantation.